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ABSTRACT 
Anna C. Leath 
USE OF MURINE MODELS TO TEST NOVEL GENE TRANSFER 
STRATEGIES FOR THE TREATMENT OF FANCONI ANEMIA 
 
The dawn of the genetic era has allowed for investigation of gene transfer 
therapy as a treatment for certain diseases. Fanconi anemia (FA) is a rare 
genetic disorder in which the majority of patients develops progressive bone 
marrow failure (BMF) and require bone marrow transplantation. A possible 
alternative treatment is autologous gene therapy; however, original clinical trials 
involving gene transfer for FA were unsuccessful. This has led to re-evaluation of 
the gene transfer protocols, the vectors and also a deeper investigation of the FA 
pathway itself. My work has focused on illuminating these areas to further 
advance gene transfer therapy for FA. 
Many gene transfer protocols require the hematopoietic stem and 
progenitor cells (HSC/HPC) to be collected and then transduced ex vivo. The 
most common collection method is mobilization of the HSC/HPC to the peripheral 
blood (PB) using granulocyte colony-stimulating factor (G-CSF) and collection via 
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apheresis. In FA patients G-CSF fails to mobilize a sufficient number of 
HSC/HPC. This has led to research into agents such as AMD3100, a CXCR4 
antagonist, which may replace or augment G-CSF mobilization. These data show 
in two FA murine models that AMD3100 synergizes with G-CSF resulting in a 
significant increase in mobilization as compared to G-CSF alone. 
Previous work in our lab has shown that prototype foamy virus (FV) is an 
efficient gene transfer vector. Here a modified FV vector is used to transduce 
mobilized FA cells. The data indicate that long-term repopulating cells mobilized 
with both G-CSF and AMD3100 can be efficiently transduced by our FV vector. 
Clinically, FA is characterized mainly by BMF, but also by myelodysplasia (MDS) 
and acute myeloid leukemia (AML). However, current FA murine models do not 
display these disease phenotypes. These data show that double-mutant Fancc-/-
;Fancg-/- mice spontaneously develop BMF, MDS and complex random 
chromosomal abnormalities that the single-mutant mice do not. Importantly, this 
model closely recapitulates the phenotypes found in FA patients and may be 
useful as a preclinical platform to evaluate the molecular pathogenesis of 
spontaneous BMF and MDS in FA and novel gene transfer protocols for FA. 
D. Wade Clapp, M.D., Chair 
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CHAPTER 1 
Introduction 
 
In the last 60 years the dawn of the genetic age has occurred. The 
knowledge and understanding of genes, their products and molecular techniques 
have allowed us to delve further into genetic understanding and manipulation 
than ever before. This new era allows for identification of individual genes and 
their products’ roles in normal cellular functions and also in disease phenotypes. 
For those diseases that are caused by a single gene defect, it has been 
hypothesized that adding a functional copy of that single gene would result in 
correction of the disease, a process termed gene therapy. 
Perhaps the most straightforward organ system in which to perform this 
type of correction is the hematopoietic system. The hematopoietic system is 
rather unique in that it is continually replenished throughout the life of an 
individual with new cells derived from hematopoietic stem cells (HSC). In order to 
correct a disease phenotype that mainly affects the hematopoietic system, focus 
can be put on correcting the defective gene in the HSC, which will then result in 
the repopulation of the entire hematopoietic system with cells containing the 
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corrected gene. The practice of removing part of the HSC population is common 
(bone marrow aspiration, mobilization and apheresis), which allows for 
exploration of the collection of the HSC for gene transfer therapy (Rosenbeck, 
Srivastava et al. 2010). Therefore, diseases that affect the hematopoietic system 
due to a mutation in a single gene are prime candidates for gene transfer 
therapy. 
While various gene transfer strategies provide potential treatments for 
patients with these types of diseases, the protocols have not been as 
straightforward to implement as originally hoped. Collectively, the scientific 
community has found that there are overall challenges when attempting gene 
transfer as well as specific challenges for each different disease. 
When considering gene transfer therapy for the hematopoietic system, 
one essential question is how to eliminate the diseased hematopoietic system. 
One approach is to start with a disease that does this on its own. In Fanconi 
anemia (FA) the majority of patients present with a progressive bone marrow 
failure (BMF), where the hematopoietic system stops making new blood cells 
(Auerbach, Buchwald et al. 2002). Also, each patient with this disease has been 
found to have a defect in only a single gene (Auerbach, Buchwald et al. 2002). 
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For FA patients, there are few curative options available (Bagby and Alter 2006). 
In FA patients (with a spontaneous reversion to correct the gene defect) 
(Waisfisz, Morgan et al. 1999; Gregory, Wagner et al. 2001; Gross, Hanenberg et 
al. 2002; Soulier, Leblanc et al. 2005; Mankad, Taniguchi et al. 2006) and also in 
FA mouse models it has been shown that wildtype (WT) cells have a competitive 
advantage over FA cells (Gush, Fu et al. 2000; Galimi, Noll et al. 2002; Haneline, 
Li et al. 2003). Together, this evidence indicates that FA is a good target disease 
for gene transfer therapy. 
While the basic concept of gene transfer therapy for FA is straightforward, 
actual implementation is extremely complex. Clinical trials failed to detect long-
term engraftment of transduced cells in patients (Liu, Young et al. 1997; Liu, Kim 
et al. 1999; Kelly, Radtke et al. 2007). Additionally, the use of murine models 
found that the ex vivo manipulation necessary for the gamma-retrovirus 
transduction protocol led to increased apoptosis of the FA cells and an increase 
in the development of clonal evolution (Li, Le Beau et al. 2005). This 
necessitated the re-evaluation of both the gene transfer vector and protocol in 
relation to FA and also a more complete understanding of the FA pathway. 
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FA is a heterogeneous genetic disease. To date, 13 genes have been 
identified as FA genes (Fanca, -b, -c, -d1, -d2, -e, -f, -g, -i, -j, -l, -m, -n) 
(Strathdee, Duncan et al. 1992; Strathdee, Gavish et al. 1992; Wevrick, Clarke et 
al. 1993; Pronk, Gibson et al. 1995; Whitney, Thayer et al. 1995; Lo Ten Foe, 
Rooimans et al. 1996; Sinoula Apostolou 1996; Joenje, Oostra et al. 1997; de 
Winter, Waisfisz et al. 1998; de Winter, Leveille et al. 2000; de Winter, van der 
Weel et al. 2000; Hejna, Timmers et al. 2000; Joenje, Levitus et al. 2000; Joenje 
and Patel 2001; Timmers, Taniguchi et al. 2001; Taniguchi and Dandrea 2002; 
Bagby 2003; Meetei, de Winter et al. 2003; Meetei, Sechi et al. 2003; Levitus, 
Rooimans et al. 2004; Levitus, Waisfisz et al. 2005; Levran, Attwooll et al. 2005; 
Meetei, Medhurst et al. 2005; Niedernhofer, Lalai et al. 2005; Bagby and Alter 
2006; Taniguchi and D'Andrea 2006; Dorsman, Levitus et al. 2007; Rahman, 
Seal et al. 2007; Reid, Schindler et al. 2007; Sims, Spiteri et al. 2007; 
Smogorzewska, Matsuoka et al. 2007; Xia, Dorsman et al. 2007). Another 2 
genes have been identified as having gene products that associate with the 
pathway (FA associated protein 24 and FA associated protein 100), but have not 
yet been found as a defective gene in a FA patient, which is a requirement to be 
Fanconi anemia 
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classified as an FA gene (Ciccia, Ling et al. 2007; Ling, Ishiai et al. 2007). 
Recently, RAD51C was identified as defective in a patient whose cells are 
hypersensitive to MMC, one of the initial diagnostic tests for FA (Meindl, 
Hellebrand et al. 2010; Vaz, Hanenberg et al. 2010). This patient has not yet 
developed BMF, so this is not officially an FA gene yet, however, it is assumed 
that this will be Fanco (Meindl, Hellebrand et al. 2010; Vaz, Hanenberg et al. 
2010). 
FA is primarily an autosomal recessive disease, only one 
complementation group, Fancb, is X-linked recessive (Meetei, Levitus et al. 
2004; Bagby and Alter 2006). All of the FA mutations result in chromosomal 
instability (Bagby and Alter 2006). The overall incidence of FA in the population is 
1 in 350,000 births, so FA is a very rare disorder with approximately 3000 
patients listed in the International Fanconi Anemia Registry (Kutler, Singh et al. 
2003). 
Diagnosis is based on hypersensitivity of the patient’s cells to cross-linking 
agents and then further analysis to determine complementation group (Green 
and Kupfer 2009). FANCA is mutated in the majority of patients and together with 
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FANCC and FANCG these three complementation groups account for over 90% 
of FA patients (Kutler, Singh et al. 2003). 
Currently the best option for an FA patient is HSC transplantation 
(Gluckman, Broxmeyer et al. 1989; Gluckman, Auerbach et al. 1995; Gluckman 
and Rocha 2005; Green and Kupfer 2009). However, the majority of patients are 
not able to find an HLA-matched donor, which leaves them with few options 
(Kutler, Singh et al. 2003). In the last decade a purine analog, fludarabine, has 
been used as part of a conditioning regimen before transplantation, and has 
been shown to reduce the incidence of graft-versus-host disease and 
transplantation-related mortality for both HLA-matched and unmatched 
transplantation (MacMillan and Wagner 2010). However, even though HSC 
transplantation is often referred to as a “curative” option, the incidence of solid 
tumors and squamous cell carcinomas among these patients is very high 
(Rosenberg, Socie et al. 2005). A reduction in myelopreparation may decrease 
the chance of these malignancies; however, addressing whether 
myelopreparation is necessary in patients with BMF is difficult. A mouse model of 
FA that develops BMF would be useful for these experiments. Other therapies 
such as androgen supplementation also provide some therapeutic benefit to 
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patients (Muller and Williams 2009); however, autologous transplantation of gene 
transfer corrected HSC would be a welcome treatment option. 
In order to understand the approach taken for gene transfer it is necessary 
to understand the underlying causes of FA. FA was originally described by Dr. 
Guido Fanconi as a genetic disorder that resulted in anemia (Fanconi 1967). 
Further studies have found that patients can also present with myeloid 
malignancies and solid tumors (Bagby and Alter 2006; Green and Kupfer 2009). 
The genes that are mutated in FA patients are spread throughout the 
genome (Schmid and Fanconi 1978; Strathdee, Duncan et al. 1992; Pronk, 
Gibson et al. 1995; Whitney, Thayer et al. 1995; Sinoula Apostolou 1996; Joenje, 
Oostra et al. 1997; de Winter, Waisfisz et al. 1998; Cheng, van De Vrugt et al. 
2000; Hejna, Timmers et al. 2000; Joenje and Patel 2001; Timmers, Taniguchi et 
al. 2001; Yang, Kuang et al. 2001; Meetei, de Winter et al. 2003; Tonnies, Huber 
et al. 2003; Meetei, Levitus et al. 2004; Levitus, Waisfisz et al. 2005; Dorsman, 
Levitus et al. 2007). The FA gene products lack homology with other known 
proteins that may give clues to their function. The exceptions are Fancl, which is 
an E3 ubiquitin ligase, and Fancj and Fancm, which have DNA helicase domains 
(Meetei, de Winter et al. 2003; Levitus, Waisfisz et al. 2005; Levran, Attwooll et 
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al. 2005; Meetei, Medhurst et al. 2005). The Fanconi anemia proteins are known 
to function in a pathway together which is thought to primarily function in the 
repair of DNA cross-links caused by agents such as mitomycin C (MMC) or 
diepoxybutane (DEB) (de Winter and Joenje 2009). The pathway is an active 
area of investigation. Some of the FA proteins form a core nuclear complex 
(thought to consist of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, 
FANCL and FANCM) that functions to monoubiquitinate the phosphorylated 
FANCD2/FANCI complex (ID complex) in response to DNA damage (Dorsman, 
Levitus et al. 2007; Grompe and van de Vrugt 2007; Sims, Spiteri et al. 2007; 
Smogorzewska, Matsuoka et al. 2007; Ishiai, Kitao et al. 2008). The 
monoubiquitinated form of the ID complex then translocates to chromatin where it 
functions with BRCA1, BRCA2 and RAD51 in nuclear foci thought to be sites of 
DNA repair (Figure 1) (Dorsman, Levitus et al. 2007; Grompe and van de Vrugt 
2007; Sims, Spiteri et al. 2007; Smogorzewska, Matsuoka et al. 2007; Ishiai, 
Kitao et al. 2008). Inactivation of any of the FA core complex proteins results in 
complete failure to monoubiquitinate the ID complex, leading to cellular 
hypersensitivity to DNA cross-linking agents (de Winter and Joenje 2009).  
 9 
 
 
Figure 1 
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Figure 1. The hypothesized Fanconi anemia DNA repair pathway. Upon DNA 
damage the FA core complex forms in the nucleus (known interacting proteins: 
FANCA, -B, -C, -E, -F, -G, -L, -M, FAAP24 and FAAP100). The FA core complex 
monoubiquitinates both FANCD2 and FANCI (ID complex). The ID complex then 
translocates to the DNA repair focus and functions with other Fanconi proteins 
(FANCD1, -J, -N, -O) as well as non-Fanconi DNA repair proteins (BRCA1, 
RAD51) in the repair of DNA cross-links. Currently the FA pathway is not fully 
understood and an active area of investigation (modified from H. Hanenberg). 
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The FA core complex proteins were originally thought to have a singular 
function: their interactions in the core complex that resulted in the 
monoubiquitination of the ID complex. However, recent evidence has pointed to 
functions for these core complex proteins in maintenance of normal 
hematopoiesis independent of the core complex (Pang, Fagerlie et al. 2000; 
Pang, Christianson et al. 2001; Zhang, Li et al. 2004; Hussain, Wilson et al. 
2006; Leveille, Ferrer et al. 2006; Mukhopadhyay, Leung et al. 2006; Wilson, 
Yamamoto et al. 2008). However, this hypothesis has not yet been evaluated 
using a genetic model. Murine knockouts of the homologues of FANCA (Fanca), 
FANCC (Fancc), FANCG (Fancg), FANCD1 (FancD1), FANCD2 (Fancd2) and 
FANCM (Fancm) have been established (Bakker, van de Vrugt et al. 2009; 
Parmar, D'Andrea et al. 2009). Although cells from all strains of FA knockout 
mice are hypersensitive to MMC, none of these single knockout mice display 
spontaneous aplastic anemia or myeloid malignancies characteristic of FA in 
patients (Bakker, van de Vrugt et al. 2009; Parmar, D'Andrea et al. 2009). 
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Currently, the most common method used to collect HSC/hematopoietic 
progenitor cells (HPC) from patients is mobilization of the HSC/HPC from the 
bone marrow to the peripheral blood (PB). Mobilization is preferable to bone 
marrow aspiration in most cases because the procedure is safer, less painful, 
results in a shorter anemic period after transplantation and also results in a 
decreased incidence of disease after transplantation (To, Haylock et al. 1997; 
Korbling and Anderlini 2001). Agents that can be used for mobilization include 
cytokines such as G-CSF (Duhrsen, Villeval et al. 1988; Socinski, Cannistra et al. 
1988), chemotherapy (Richman, Weiner et al. 1976) and even exercise (Barrett, 
Longhurst et al. 1978). While evidence that HSC/HPC exist at low levels in the 
peripheral blood has been published (Goodman and Hodgson 1962; McCredie, 
Hersh et al. 1971), the realization that HSC/HPC could be mobilized from the 
bone marrow to the PB resulted directly from observations in patients. The first 
notice of mobilization came from a group who quantified an increase in the 
number of peripheral blood colony forming units after chemotherapy (Richman, 
Weiner et al. 1976).The discovery of the use of cytokines, as opposed to or in 
addition to chemotherapy, for the mobilization of stem cells allowed for more 
Mobilization 
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extensive study of mobilization (Socinski, Cannistra et al. 1988; Haas, Ho et al. 
1990; Bensinger, Clift et al. 1996). During this time, the level of CD34+ cells as a 
measure for the enrichment of HSC/HPC was being established (Bensinger, 
Longin et al. 1994; Weaver, Hazelton et al. 1995). Currently, granulocyte colony-
stimulating factor (G-CSF) is the standard mobilizing agent used in patients. 
Unfortunately, G-CSF is not effective as effective in mobilizing CD34+ cells in FA 
patients as in normal patients (Croop, Cooper et al. 2001). This has also been 
found true for other genetic disorders such as chronic granulomatous disease 
and adenosine deaminase-deficient severe combined immunodeficiency patients 
(Sekhsaria, Fleisher et al. 1996), and also in up to 15% of normal individuals 
(Moncada, Bolan et al. 2003). 
These observations led to research into the mechanism of G-CSF 
mobilization, which provided new directions for mobilization protocols. Many 
papers pointed to matrix metalloproteinases as the main mechanism for G-CSF 
induced mobilization, specifically neutrophil elastase (NE) and cathepsin G (CG) 
(Levesque, Takamatsu et al. 2001; Levesque, Hendy et al. 2002) or matrix 
metalloproteinase 9 (MMP9) (Pruijt, Fibbe et al. 1999; Heissig, Hattori et al. 
2002; Levesque, Hendy et al. 2002). Their hypothesis was that the neutrophils 
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were degranulating in the bone marrow stroma and that the disruption of the 
HSC/stromal cell interactions by the proteinases released in the environment 
resulted in mobilization. This hypothesis was further supported by the 
observations that NE and CG both act on vascular cell adhesion molecule-1 
(VCAM-1) and that disruption of the interaction of VCAM-1 with very late antigen-
4 (VLA-4) results in mobilization of HSC/HPC (Levesque, Takamatsu et al. 2001; 
Levesque, Hendy et al. 2002; Levesque, Liu et al. 2004). However, mice deficient 
in NE and CG still had normal mobilization in response to G-CSF (Levesque, Liu 
et al. 2004), which led to investigation of other HSC/stromal cell interactions. 
Other ligands to receptors known to function in stem cell tethering have been 
shown to induce mobilization, such as soluble c-Kit receptor (Nakamura, Tajima 
et al. 2004) and Fms-like tyrosine kinase 3 (Flt-3) ligand (Reeves, Wei et al. 
2010). Another involves chemokine (C-X-C motif) ligand 12 (CXCL12) also 
known as stromal cell-derived factor-1 (SDF-1) interacting with CXCR4, also 
known as fusin. The release of NE and CG disrupts the interaction between the 
HSC and the stromal cell by disrupting the SDF-1 chemotactic gradient in the 
bone marrow (Petit, Szyper-Kravitz et al. 2002; Levesque, Hendy et al. 2003) 
and also by decreasing the responsiveness of the HSC to the SDF-1 chemotactic 
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gradient (Levesque, Hendy et al. 2003; Levesque, Liu et al. 2004). Dipeptidyl 
peptidase-4, also known as cluster of differentiation 26 (CD26), has also been 
shown to disrupt the SDF-1 gradient. CD26, a peptidase expressed on the 
surface of myeloid cells and bone marrow HSC/HPC can cleave and inactivate 
SDF-1 (Bongers, Lambros et al. 1992). Additionally, HSC/HPC mobilization is 
reduced by 50 to 80% in CD26-/- mice (Christopherson, Cooper et al. 2003; 
Christopherson, Cooper et al. 2003). Cells treated with CD26 inhibitors have 
been shown to have increased engraftment (Christopherson, Hangoc et al. 2004; 
Broxmeyer, Hangoc et al. 2007; Campbell, Hangoc et al. 2007). 
The above observations led to research into the administration of 
antagonists to molecules known to help in retention of HSC in the stroma. One 
such inhibitor is AMD3100 (more recently known as plerixafor), a small molecule 
that is an antagonist to CXCR4, the receptor for SDF-1. Previous studies have 
shown that administration of AMD3100 in addition to G-CSF results in a 
synergistic increase in the mobilization of HSC in WT mice and HPC in Fancc-/- 
mice (Broxmeyer, Orschell et al. 2005). Ideally this method can be used to obtain 
sufficient numbers of HSC/HPC from FA patients; however, whether this 
combination of agents will result in increased mobilization of HSC/HPC in our FA 
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mouse models needs to be determined first. Additionally, there is evidence that 
the mobilized cell population does not respond to transduction in the same 
manner as the BMC population (Hematti, Sellers et al. 2003; Thomasson, 
Peterson et al. 2003), perhaps due to mobilization’s effects on cell surface 
receptors or other biochemical changes in the cells. Therefore studying the 
transduction of mobilized HSC/HPC in our murine model is necessary. 
Interestingly, recent evidence points to a role for reduction-oxidation 
reaction (redox) regulation of stem cell mobilization. Many of the signal 
transduction pathways leading to cytokine expression are redox regulated (Lekli, 
Gurusamy et al. 2009). In the bone marrow niche, HSC are in a hypoxic 
environment and upon mobilization they enter an oxygenic environment (Lekli, 
Gurusamy et al. 2009). FANCG is known to interact in redox pathways in the 
mitochondria (Mukhopadhyay, Leung et al. 2006). Further investigation into the 
redox pathways’ regulation of mobilization may provide a link that helps explain 
the FA mobilization defect. 
Additional evidence has recently been published supporting the argument 
for the innate immune response also having a role in mobilization (Lee, Wu et al. 
2009; Jalili, Marquez-Curtis et al. 2010; Jalili, Shirvaikar et al. 2010; Lee, 
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Wysoczynski et al. 2010). Both AMD3100 and G-CSF mobilization were found to 
depend on complement activation, but at different steps in the pathway. 
AMD3100 activates complement component 5 (C5) via granulocyte protease 
release (Lee, Wysoczynski et al. 2010), whereas G-CSF activates complement at 
some point upstream of complement component 3 (C3) (Lee, Wu et al. 2009; 
Jalili, Shirvaikar et al. 2010; Lee, Wysoczynski et al. 2010). Since FA mice 
mobilize well in response to AMD3100, but not to G-CSF, there may be some 
disruption in the complement pathway before the C5 activation step. 
The mechanism of HSC mobilization is an active area of investigation. The 
studies here have focused on evaluating AMD3100 for the augmentation of G-
CSF mobilization in FA murine models. 
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Foamy virus was first isolated from Rhesus macaque kidney cells in 1955 
(Rustigian, Johnston et al. 1955). Foamy virus has since been found in many 
other mammals including: African green monkey (Neumann-Haefelin, Fleps et al. 
1993), chimpanzee (Herchenroder, Renne et al. 1994), gorilla (Bieniasz, 
Rethwilm et al. 1995), baboons (Broussard, Comuzzie et al. 1997), and many 
others. In 1971 a human foamy virus was isolated from the lymphoblastoid cells 
in a nasopharyngeal carcinoma from a Kenyan patient (Achong, Mansell et al. 
1971; Achong, Mansell et al. 1971). The sequence of “human foamy virus” was 
found to be greater than 95% identical to the simian foamy virus isolated from 
Pan troglodytes schweinfurthii and was renamed SFVcpz(hu) (Herchenroder, 
Renne et al. 1994) and is now referred to as prototype foamy virus (FV). 
Prototype foamy virus 
FV is in the retrovirus family, genus spumavirus. The virus reverse 
transcribes its RNA genome to DNA either before leaving the host cell or in the 
virion form (before entering the cell it is infecting) (Moebes, Enssle et al. 1997; 
Yu, Sullivan et al. 1999). This is also characteristic of hepadnaviruses (reviewed 
in (Beck and Nassal 2007)). Because the virions contain a DNA genome it is 
thought that they may be more stable than retrovirus or lentivirus vectors 
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(Moebes, Enssle et al. 1997; Yu, Sullivan et al. 1999). The FV genome is 
approximately 13kb and contains 5 genes: gag, pol, env, tas and bet (Figure 2) 
(Lochelt, Zentgraf et al. 1991). The gag gene encodes structural proteins and 
differs from other retroviruses in that it retains an immature morphology, meaning 
it is not cleaved (Meiering and Linial 2001). The pol gene encodes a protein with 
reverse transcriptase, integrase and protease domains (Meiering and Linial 
2001). The env gene encodes the envelope protein, which contains an 
endoplasmic reticulum retention signal (Goepfert, Wang et al. 1995). The tas 
gene (also known as bel-1) is required for replication, it encodes the protein that 
transactivates the long terminal repeat (LTR) promoter (Lochelt, Zentgraf et al. 
1991; Mergia, Shaw et al. 1991; Rethwilm, Erlwein et al. 1991). The last gene, 
bet, codes for the alternative splicing products: bet, bel-2 and bel-3, whose 
function in the FV life cycle is an active area of investigation. It is thought that bet 
may function in disrupting the antiviral activity of apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3 (APOBEC3) (Perkovic, Schmidt et al. 2009). 
There are 2 “packaging” signals in the genome, cis-acting sequences I and II 
(CAS I and CAS II), when these are not present the RNA genome will not be 
packaged into the virion (Meiering and Linial 2001). 
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Figure 2 
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Figure 2. FV genome. Schematic representation of the FV genome with the viral 
genes gag, pol, env, Tas and Bet. IP is the internal promoter for the expression 
of Tas. CAS I and II depict the discontinuous packaging signal residing in the cis-
acting sequences I and II. 
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Upon entering the cell, the virus will locate near the centrosome and wait, 
still capsulated, for up to 2 weeks (Lehmann-Che, Renault et al. 2007). Upon the 
cell dividing, the virion will shed its capsule and the POL protein will coordinate 
the viral genome integration into the cellular DNA. Therefore, unlike retrovirus 
vectors, FV does not require immediate cell cycling to integrate its genome so 
there is no need to stimulate cells to cycle in vitro (Lehmann-Che, Renault et al. 
2007). Upon integration the tas transactivator will then drive transcription from 
the LTR promoter (Meiering and Linial 2001). Transcription of the viral genome 
begins and the proteins are synthesized. The virions exit the cell via exocytosis 
using vesicles from the endoplasmic reticulum (Meiering and Linial 2001). 
While infection with FV results in cytopathic effects including rapid 
syncytium formation, cytoplasmic vacuolization, and cell death (Meiering and 
Linial 2001), current self-inactivating gene transfer vectors have not reported 
these cytopathic effects (Bauer, Allen et al. 2008; Si, Pulliam et al. 2008; Erlwein 
and McClure 2010). Foamy viral transmission is not fully understood, although it 
is thought to be through saliva (Johnson, de la Rosa et al. 1988; Broussard, 
Comuzzie et al. 1997; Meiering and Linial 2001) and blood (Brooks, Merks et al. 
2007). Humans are not typically seropositive for FV unless directly in contact with 
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non-human primates (Achong and Epstein 1978; Brown, Nemo et al. 1978; 
Nemo, Brown et al. 1978; Loh, Matsuura et al. 1980; Muller, Ball et al. 1980; 
Achong and Epstein 1983; Mahnke, Kashaiya et al. 1992; Schweizer, Turek et al. 
1995; Ali, Taylor et al. 1996). There is no evidence of horizontal transfer from 
human to human (Erlwein and McClure 2010). FV results in chronic, persistent 
infections in both simians and humans (Johnston 1961; Hooks and Gibbs 1975; 
Johnson, de la Rosa et al. 1988; Kertayadnya, Johnson et al. 1988; Schweizer, 
Falcone et al. 1997; Heneine, Switzer et al. 1998) and also in certain cell types in 
culture such as myeloid, lymphoid and erythroid (Cringle, Yu et al. 1996; Mergia, 
Leung et al. 1996; Mikovits, Hoffman et al. 1996). Chronic infections may mean 
that the FV gene transfer vector will result in the protein being expressed long-
term in the patient’s cells.  
FV is not associated with any diseases or symptoms in natural hosts or 
humans and it has broad host and tissue tropism (Mergia, Shaw et al. 1991; Hill, 
Bieniasz et al. 1999). FV has a large genome, so it can carry and transfer large 
genes, up to 9.2kb (Lochelt, Zentgraf et al. 1991; Erlwein and McClure 2010). 
Also, FV has a high genetic stability which is important for gene transfer because 
the transgene sequence needs to remain intact (Schweizer, Schleer et al. 1999). 
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Past gene therapy trials for severe combined immunodeficiency using a 
retrovirus vector resulted in integration by the LIM domain only 2 (LM02) 
promoter, resulting in leukemia (Hacein-Bey-Abina, Von Kalle et al. 2003). Many 
recent studies have addressed the integration profile of FV, to determine the risk 
of insertional mutagenesis. Unlike the gamma-retroviral vectors which have been 
shown to integrate preferentially near proto-oncogenes, FV has a small 
preference toward transcription start sites and CpG islands (Trobridge, Miller et 
al. 2006; Beard, Keyser et al. 2007; Rethwilm 2007; Bauer, Allen et al. 2008), 
which may mean that FV will be less likely to induce insertional mutagenesis. 
Further analysis of the FV integrase protein is ongoing and may lead to a 
greater understanding of integration and even allow for targeting integration to 
specific areas. Additionally, development of integration assays to detect 
activation of nearby genes have also indicated that FV, when combined with a 
promoter such as the phosphoglycerate kinase (PGK) promoter, is much less 
likely to result in the activation of nearby genes than retrovirus also with a PGK 
promoter (Hendrie, Huo et al. 2008).  
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CHAPTER 2 
Materials and methods 
 
Fanca-/- mice (Cheng, van De Vrugt et al. 2000), Fancc-/- mice (Chen, 
Tomkins et al. 1996) and Fancg-/- mice (Yang, Kuang et al. 2001) 
(C57Bl/6xSV129) were backcrossed 10 generations into a C57BL/6J strain 
(CD45.2+) as described previously (Haneline, Li et al. 2003; Si, Ciccone et al. 
2006). Mice deficient in both Fancc and Fancg were generated by mating 
Fancc+/- with Fancg+/- to obtain double heterozygous mice (F1). These mice 
were then used to generate the homozygous Fancc-/-;Fancg-/- mutant mice (F2).  
Experimental animals 
Congenic wildtype C57BL/6J (WT) mice (CD45.2+) and wildtype B6.SJL-
Ptrca Pep/BoyJ (BoyJ) mice (CD45.1+) were originally purchased from Jackson 
ImmunoResearch Laboratories (Bar Harbor, ME) and are maintained in our 
animal facility. The Institutional Animal Care and Use Committee of Indiana 
University approved all studies. 
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G-CSF (Amgen Corp., Thousand Oaks, CA) was administered at a dose 
of 3µg subcutaneously (s.c.) in 0.1ml phospho-buffered saline/0.1% bovine 
serum albumin (PBS/0.1% BSA) every 12 hours for four consecutive days as 
described previously (Broxmeyer, Orschell et al. 2005). Control animals received 
a similar volume of PBS/0.1% BSA for four consecutive days. AMD3100 
(provided by Dr. Gary Bridger, AnorMed, Inc., Langley, British Columbia) was 
administered at a dose of 5mg/kg s.c. 14 hours following the last dose of G-CSF 
and one hour prior to the collection of PB. Low-density mononuclear cells 
(LDMC) were isolated from the PB using Ficoll Hystopaque-1119 (Sigma-Aldrich, 
St. Louis, MO), washed in PBS/0.1% BSA and resuspended in Gibco Iscove’s 
Modified Dulbecco’s Medium (IMDM) (Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO). 
Drug administration and isolation of low-density mononuclear cells 
 
Clonogenic methylcellulose assays were performed in triplicate in 35mm 
plates (Becton Dickinson, Franklin Lakes, NJ). LDMC from 0.1ml PB for 
mobilization experiments or 2.0 X 104 for bone marrow cells (BMC) were cultured 
Hematopoietic progenitor assays (colony assays) 
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per plate. Cells were cultured in 1.04% methylcellulose (Stem Cell Technologies, 
Vancouver, BC) in Gibco IMDM (Invitrogen, Carlsbad, CA) supplemented with 
30% FBS (Sigma-Aldrich, St. Louis, MO), BioWhittaker penicillin 
(100U/ml)/streptomycin (100µg/ml) (P/S) (Invitrogen, Carlsbad, CA), 2mM 
BioWhittaker L-glutamine (Invitrogen, Carlsbad, CA) and 71.5µM 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO). Assays were supplemented 
with the following cytokines from Peprotech (Rocky Hill, NJ): 200ng/ml murine 
stem cell factor, 10ng/ml murine granulocyte macrophage colony-stimulating 
factor, 5ng/ml murine interleukin 3 and with 4U/ml human recombinant 
erythropoietin from Amgen (Thousand Oaks, CA). Cells were cultured for 7 days 
at 37ºC, 5% CO2 and then scored for the presence of hematopoietic progenitor 
colonies. When indicated, assays were also supplemented with MMC (Sigma 
Aldrich, St Louis, MO) or tumor necrosis factor alpha (TNF-α) (Sigma Aldrich, St 
Louis, MO) at the indicated concentrations as described previously (Haneline, 
Broxmeyer et al. 1998; Koh, Hughes et al. 1999). In order to count the cells 
according to hematopoietic cell lineage, the colonies were stained with 1.5mg/ml 
benzidine in water with 5% glacial acetic acid and 25µl 30% H202. 
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Competitive repopulation experiments were conducted as previously 
described (Haneline, Li et al. 2003; Broxmeyer, Orschell et al. 2005; Li, Le Beau 
et al. 2005). LDMC collected from 1 ml (cohort 1) or 2 ml (cohort 2) of the PB of 
donor WT, Fanca-/- or Fancc-/- mice treated with G-CSF, AMD3100 or both were 
transplanted along with 7.5 x 105 BoyJ bone marrow LDMC into lethally irradiated 
recipients. Two independent experiments with 3-5 recipients/genotype/treatment 
were analyzed.  
Competitive repopulation assays 
For the transduced mobilized cells, after transduction cells were washed 2 
times with PBS/0.1% BSA. LDMC from the equivalent of 1 ml of peripheral blood 
were injected into lethally irradiated recipients along with 5 X 105 BoyJ bone 
marrow LDMC (n=7 per group).  
For the Fancc-/-;Fancg-/- experiments, bone marrow LDMC were isolated 
using Ficoll Hystopaque-1119 (Sigma-Aldrich, St. Louis, MO), washed in 
PBS/0.1% BSA and resuspended in Gibco Iscove’s Modified Dulbecco’s Medium 
(IMDM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(FBS) (Sigma-Aldrich, St. Louis, MO) as described previously (Haneline, Gobbett 
et al. 1999; Si, Pulliam et al. 2008). The cells were injected into the tail vein of 
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lethally irradiated recipient mice along with competitor cells from congenic BoyJ 
mice at the indicated concentrations.  
 
Eight to twelve week old WT were used as recipients. These mice were 
irradiated (1100 rads) using the gammacell-4 exactor (Nordion, Ottawa, ON, 
Canada) containing a 137Cs source. 
Lethally irradiated recipients 
 
Chimerism was measured at the indicated time points as described 
previously (Haneline, Li et al. 2003). Briefly, PB was collected from the tail of 
recipient mice. The samples were treated with red blood cell lysis buffer for 15 
minutes and then washed 2 times in PBS/0.1% BSA. They were then stained 
with FITC-conjugated CD45.2 antibodies (BD Biosciences, San Jose, CA) for 30 
minutes at 4ºC in the dark. They were then washed with PBS/0.1% BSA once 
and the percentage of positive cells was determined by flow cytometry. Mean 
donor chimerism was analyzed to evaluate for significant differences between 
groups. 
Chimerism 
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Four months after transplantation, LDMC were collected from the bone 
marrow of primary recipients and 2 x 106 LDMC were transplanted into lethally 
irradiated recipients to test self-renewal capacity as described previously 
(Broxmeyer, Orschell et al. 2005).  
Secondary transplantation 
 
Multi-lineage analysis was performed on the indicated cell population 
using FITC-conjugated CD45.2 and PE-conjugated CD3 or Mac-1 and APC-
conjugated Gr-1 or B220 antibodies (BD Biosciences, San Jose, CA). The 
percentage of cells double positive for CD45.2 and the specific lineage marker 
was determined using flow cytometry. 
Multi-lineage flow analysis 
 
Repopulating units (RU) were calculated using the following equation 
(Harrison 1980; Haneline, Li et al. 2003; Li, Le Beau et al. 2005): RU = 
(competitor number x % donor chimerism)/(100 - % donor chimerism). 
Repopulating units 
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The indicated statistical test was performed using GraphPad Prism 4. (La 
Jolla, CA).  
Statistical analysis 
 
The foamyviral constructs used in our studies were derivatives of the MD9 
construct (Heinkelein, Dressler et al. 2002), a kind gift of Axel Rethwilm 
(Würzburg, Germany). In the MD9 vector, all foamyviral genes and also the 
enhancer elements in the 3’ U3 region (Figure 8) have been functionally 
inactivated by partial deletions. The remaining noncoding 5’ region of GAG and 
the 3’ region of POL are harboring the packaging signals (CAS I and II) and are 
therefore essential for the production of recombinant foamyviral particles 
(Heinkelein, Dressler et al. 2002). A linker was cloned into the Not I site 3’ of 
MD9 and then an expression cassette containing the encephalomyelocarditis 
virus (EMCV) internal ribosomal entry site (IRES) and the enhanced green 
fluorescence protein (EGFP) cDNAs introduced from S11IEG3 via BamH I and 
Spe I, thereby creating the MD9-EGFP construct. The human FANCC cDNA was 
cloned into the BamH I site resulting in the MD9-FANCC/EGFP vector. 
Foamyviral vectors 
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Self-inactivating FV vectors were produced by transfection of 293T cells. 
Briefly, 8 X 106 293T were plated on 10cm tissue culture treated plates. The 
following morning, media was aspirated off and replaced with 4ml fresh Gibco 
high glucose Dulbecco’s modified eagle’s medium (DMEM) (Invitrogen, Carlsbad, 
CA) supplemented with 15% FBS (heat inactivated) (Sigma-Aldrich, St. Louis, 
MO), 2mM BioWhittaker L-glutamine (Invitrogen, Carlsbad, CA) and 0.15% 
BioWhittaker sodium bicarbonate. Per plate, 5µg pcoGAG, 1µg pcoPOL, 1µg 
pcoPE01 and 10µg of the vector plasmid were mixed. The volume was brought 
up to 1ml per plate with plain high glucose DMEM. Polyethylenimine (1mg/ml) 
was diluted to 51µg/ml with plain high glucose DMEM. 1ml of 51µg/ml 
polyethylenimine was added to the plasmid mix for each plate, flash vortexed and 
incubated at room temperature for 20 minutes. After incubation, 2ml was added 
to each plate. The plates were incubated overnight at 37ºC, 5% CO2. The next 
day the media was changed on the plates (high glucose DMEM supplemented 
with 10% FBS (heat inactivated), 2mM BioWhittaker L-glutamine (Invitrogen, 
Carlsbad, CA), 100U P/S) and they were again incubated overnight at 37ºC, 5% 
CO2. The next morning the supernatant was collected and filtered through a 
Foamy viral production 
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45µm low protein-binding filter. High-speed centrifugation (>15000g, 2 hours) 
was performed to concentrate the virus, which was then resuspended in media 
(high glucose DMEM supplemented with 10% FBS (heat inactivated), 2mM 
BioWhittaker L-glutamine (Invitrogen, Carlsbad, CA), 100U P/S). Aliquots were 
taken for the titer and remaining samples were frozen at -80ºC. 
 
The following titer procedure is used to determine the number of infectious 
viral particles (IP) present in the supernatant. The day prior to collection a set 
number of HT1080 cells are plated. The next morning, the virus is collected, 
filtered, and concentrated. An aliquot is taken for serial dilution. Each of the serial 
dilution aliquots is flash frozen and then thawed and added to the HT1080 cells. 
The flash freeze allows for close approximation of how many IP will be present 
when the frozen samples are thawed for use. The media is changed after 24 
hours. At 48 hours post transduction the cells are collected and the percentage of 
cells that are GFP+ is determined using flow cytometry. This percentage is used 
to calculate how many IP were originally present: % GFP+ X starting cell # X 
1/(dilution factor) = IP/ 1 ml. Now that the number of IP per ml in our frozen 
Viral titer 
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samples of virus is known, a specific multiplicity of infection (MOI) to transduce 
our target cells can be calculated. This is a measure of how many IP are present 
per cell. The titers of the viral supernatant were 1-5 x 107 viral particles/ml for 
MD9-EGFP and 4-10 x 106 viral particles/ml for MD9-FANCC/EGFP construct 
after concentration. 
 
The mobilized LDMC were washed and resuspended in the viral 
supernatant (MOI=1) supplemented with murine interleukin 6 (200U/mL) and 
murine stem cell factor (100ng/mL) (both from Peprotech, Rocky Hill, NJ) and 
incubated on the recombinant human fibronectin fragment CH296, RetroNectinTM 
(TAKARA BIO INC., Otsu, Japan) as described previously (Hanenberg, Batish et 
al. 2002). Cells were incubated at 37ºC with 5% CO2. Cells were harvested 14 
hours following transduction and washed with PBS/0.1% BSA. 
Foamyvirus-mediated transduction 
 
Colonies of FV-transduced cells plated in progenitor assays were 
individually collected and suspended in PBS. The genomic DNA was isolated 
Amplification of genomic and proviral DNA 
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and polymerase chain reaction (PCR) for EGFP was performed: Forward 5’-
ATGGTGAGCAAGGGCGAGGAG-3’, Reverse 5’-AAGTCGTGCTGCTTCATG 
TG-3’ with the following program: 95ºC, 5 minutes; 95ºC, 40 seconds; 55ºC, 30 
seconds; 72ºC, 1 minute; cycled to step 2 for 31 cycles; 72ºC, 10 minutes and 
then stored at 4ºC and analyzed on a 1% agarose gel. The amplified product has 
a size of approximately 250bp. In addition, PCR for the genotype of the 
progenitor cells was performed. Three primers are used: 5’-GAGCAACACAAAT 
GGTAAGG-3’, 5’-CCTGCCATCTTCAGAATTGT-‘3 and 5’-TTGAATGGAAGGAT 
TGGAGC-3’ with the following program: 95ºC, 5 minutes; 95ºC, 30 seconds; 
55ºC, 2 minutes; 72ºC, 1.5 minutes; cycled to step 2 for 31 cycles; 72ºC, 10 
minutes and then stored at 4ºC and analyzed on a 1% agarose gel. The amplified 
product of the WT copy of the Fancc gene is approximately 800bp, whereas the 
knockout gene PCR product is approximately 600bp. 
 
Genomic DNA from bone marrow and spleen specimens was isolated 
using phenol-chloroform extraction and digested with Xho I (New England 
BioLabs, Ipswich, MA). Fragments were isolated via ethanol precipitation and run 
Southern blot for junctional fragment analysis 
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on a 1% agarose gel. The DNA was transferred to a nylon membrane using the 
TurboBlotterTM system (Schleicher & Schuell, Keene, NH). To generate the 
hybridization probe, the MD9 plasmid was digested with Pst I (New England 
BioLabs, Ipswich, MA) and the 1655bp fragment was isolated using QIAquick gel 
extraction kit (Qiagen, Valencia, CA), labeled using the Prime-It II Random 
Primer labeling kit (Stratagene, La Jolla, CA) and purified using a micro-spin 30 
column (Bio-Rad, Hercules, CA). The membrane was pre-hybridized for 2 hrs at 
42ºC with the hybridization solution (6X SSC, 50% Formamide, 5X Denhardt’s, 
0.5% SDS in water) supplemented with 100µg/ml denatured salmon sperm DNA 
(Stratagene, La Jolla, CA). After pre-hybridization, the membrane was hybridized 
for 16 hrs at 42ºC with the hybridization solution supplemented with 100µg/ml 
denatured salmon sperm DNA (Stratagene, La Jolla, CA) and denatured labeled 
probe. The next day, the membrane was washed four times for 15 minutes at 
42ºC with the wash solution (2X SSC, 0.1% SDS in water) and exposed to film 
(BioMax MS film Kodak, Rochester, NY) at -80ºC with a Cronex Lightning Plus 
intensifying screen (DuPont, Wilmington, DE). 
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PB was collected from the tail vein of mice and stored in microtainer brand 
tubes with EDTA (Becton Dickinson, Franklin Lanes, NJ). Complete blood counts 
were performed using a Hemavet950 (Drew Scientific Group, Dallas, TX). The 
remaining blood was then treated with red cell lysis buffer (Gentra Systems, 
Minneapolis, MN) for 15 minutes at room temperature. The cells were washed in 
PBS/0.1% BSA and split into 2 aliquots. Each aliquot was stained with either 
FITC-conjugated CD45.2 or CD45.1 antibodies (BD PharMingen) at 4ºC for 20 
minutes. The cells were then washed in PBS/0.1% BSA and analyzed by flow 
cytometry. 
Complete blood counts and chimerism 
 
Spleens and humeri or tibiae from selected animals were fixed in 10% 
buffered formalin and embedded in paraffin. Sections were obtained and stained 
with hematoxylin and eosin (H&E). All histological sections were analyzed in a 
blinded fashion. 
Histology 
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Pictures were taken on a Zeiss Axioscope (Zeiss, Ontario, NY) with the 
Plan Neofluar 20x/0.50 or the Ph3 Neofluar 40X/1.30 oil (Zeiss, Ontario, NY). 
Images were captured using a SPOT RT Color camera, model 2.2.1 (Diagnostic 
Instruments, McHenry, IL) and edited using SPOT Advanced software version 
4.1.2 (Diagnostic Instruments, McHenry, IL). 
Microscopy 
 
Cytogenetic analysis was performed on BMC from non-competitive 
transplantation recipients as described (Lee, Warburton et al. 1990). Briefly, 
short-term, synchronized cultures were initiated and metaphase cells were 
prepared using standard cytogenetic techniques following mitotic arrest with 1% 
colcemid (10µg/ml, Invitrogen Life Technologies, Grand Island, NY). Between 
five and 15 G-banded metaphase cells were completely analyzed for each 
culture. Mouse chromosomes were classified utilizing standardized mouse 
chromosome ideograms and following nomenclature standards of the 
International Committee on Standard Genetic Nomenclature for Mice 
(
Cytogenetic Analysis  
http://www.informatics.jax.org/mgihome/nomen/anomalies.shtml). 
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Spectral karyotyping (SKY) was performed utilizing mouse reagents 
(SkyPaint for mouse, Applied Spectral Imaging (ASI), Carlsbad, CA) and 
following the manufacturer’s protocol for mouse chromosome analysis with the 
exception of a longer hybridization time of 42 hours. Fluorochromes utilized 
included: rhodamine, Texas red, Cy5, FITC and Cy5.5. An interferogram for each 
metaphase was generated using a SD200 Spectracube (ASI) mounted to a Leica 
DM 5000 fluorescence microscope. Three to ten metaphase cells were captured 
and karyotyped for each culture. 
SKY analysis  
 
RNA was isolated using the RNeasy Mini Kit (Qiagen, Germantown, MD) 
from whole BMC obtained from 3-month-old syngeneic mice (WT, Fancc-/-, 
Fancg-/- and Fancc-/-;Fancg-/-). Microarray assays were performed in the 
Affymetrix Microarray Core, a unit of the Gene Microarray Shared Resource 
located in the Knight Cancer Institute at Oregon Health and Science University, 
Portland, OR. Hybridization targets were prepared from 2µg total RNA using the 
one cycle cDNA, IVT amplification/labeling protocol procedure as described in 
RNA isolation and GeneChip Array 
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the Affymetrix GeneChip Expression Analysis Technical Manual, rev.5 
(Affymetrix, Santa Clara, CA). After fragmentation, each sample target was 
hybridized to an MOE 430 2.0 GeneChip array, a chip containing 45,000 probe 
sets that measure the expression level of >39,000 transcripts and variants from 
>34,000 well-characterized mouse genes (Affymetrix, Santa Clara, CA). 
Scanning was performed with the Affymetrix 3000 GeneArray Scanner and 
image processing and expression analysis were performed using Affymetrix 
GeneChip Operating Software (GCOS) v1.2 software. The quality of project 
hybridizations was assessed using: 1) performance metrics extracted from the 
GCOS report file for each array and 2) pair-wise scatter plots of the ‘absolute 
analysis’ data from each array assay.  
 
At the 1.5 fold threshold in double mutant cells, 3,197 genes were 
differentially expressed in the pairwise comparison with WT cells. Only 520 and 
304 genes were differentially expressed (as compared to WT) in Fancc and 
Fancg single mutant cells, respectively. Of the 520 (Fancc mutant), 263 were 
found in the set of 3,197 genes. Of the 304 (Fancg mutant), 216 were found in 
Microarray Data Management and Analysis 
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the set of 3,197. The processed image files (.CEL) were imported into GeneSifter 
(Seattle, WA) and Partek Genomics Suite (Partek, Inc., St. Louis, MO) software 
programs. Hierarchical clustering was performed using GeneSifter for multiple 
data sets filtered by thresholds of 1.5, 2, 3, 4 and 5-fold using ANOVA (p<0.01) 
and the Benjamini-Hochberg correction for multiple comparisons. The 
dendrograms for each threshold were identical (Figure 13E shows the 
dendrogram for the 1.5-fold threshold). Principal component analysis was 
performed using both GeneSifter and Partek Genomics Suite (Figure 13F shows 
the results, for the results filtered at the 1.5-fold threshold, displayed using the 
Partek ellipsoid graphic tool). 
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CHAPTER 3 
AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi 
anemia knockout mice 
 
FA patients usually present with BMF during childhood, making bone 
marrow aspiration a difficult process. Mobilization of stem cells from the bone 
marrow into the PB for collection would be ideal. G-CSF is an FDA approved 
therapy utilized for mobilization of HSC/HPC for transplantation in a variety of 
clinical settings (Mohle and Kanz 2007). However, patients with FA show a 
markedly decreased response to G-CSF (Croop, Cooper et al. 2001). The 
inability of G-CSF to adequately mobilize HSC/HPC in FA patients has prompted 
the search for alternative methods. 
Introduction 
The interaction between bone marrow stroma and HSC via SDF-1 and 
CXCR4, respectively, plays an important role in HSC chemotaxis and retention 
within the marrow (Lapidot and Kollet 2002). AMD3100, a bicyclam derivative, is 
a competitive antagonist of this interaction and thus serves as a potential agent 
for HSC/HPC mobilization (Broxmeyer, Orschell et al. 2005). AMD3100 works 
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synergistically with G-CSF to induce mobilization of the following: wild type 
murine HSC, non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) repopulating cells from healthy human donors and HPC from 
Fancc-/- mice (Broxmeyer, Orschell et al. 2005). Further, during phase III clinical 
trials, AMD3100 has been administered to patients with multiple myeloma and 
non-Hodgkin’s lymphoma and has been shown to be an efficacious and safe 
regimen for stem cell mobilization and gained FDA approval in December 2008 
(DiPersio, Stadtmauer et al. 2009; Stiff, Micallef et al. 2009).  
There is also evidence that AMD3100 may be useful as a 
chemosensitizing agent in acute myeloid leukemia (Nervi, Ramirez et al. 2009) 
and it is in phase I/II trials for chemosensitization for chronic myelogenous 
leukemia (Pusic and DiPersio 2010). Use of AMD3100 alone in healthy patients 
is also being studied (Devine, Vij et al. 2008). Many more studies of AMD3100 
are currently ongoing (Pusic and DiPersio 2010).  
Here, the effect of AMD3100 and G-CSF on HSC mobilization is examined 
in FA types A and C murine models. The data show that the combination of 
AMD3100 and G-CSF works synergistically to mobilize HSC with long-term 
repopulating ability and self-renewal capacity in two murine models of FA.  
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In previous studies, increased mobilization of hematopoietic progenitors in 
Fancc-/- mice was assessed; however, the broad applicability of this approach to 
other FA genotypes was not determined. Given potential subtle differences in the 
phenotypes of FA genotypes in patients and various FA knockout mice, these 
studies were validated and extended in Fanca-/- mice, the murine homologue of 
the most prevalent FA complementation group in patients. Analogous to previous 
studies in WT and Fancc-/- mice, administration of G-CSF and AMD3100 
resulted in at least an additive mobilization of lineage restricted and multipotent 
hematopoietic progenitors as compared to use of either compound alone (Figure 
3). Furthermore, an increase in the mobilization of lineage restricted and 
multipotent progenitors was observed in Fanca-/- and Fancc-/- mice. 
Results 
Previous studies in Fancc-/- mice examined the mobilization of progenitors 
but not repopulating HSC (Broxmeyer, Orschell et al. 2005). Given that 
mobilization of HSC is required for effective gene therapy in FA, competitive 
repopulation was used to evaluate the ability of G-CSF and AMD3100 alone or in 
combination to mobilize repopulating stem cells in WT, Fanca-/- and Fancc-/- 
mice. A schematic of the experimental design is shown in Figure 4. 
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Figure 3 
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Figure 3. Mobilization of HPC is enhanced when both G-CSF and AMD3100 
are used. The mean total number of HPC/ml PB ± SEM of the indicated lineages 
and genotypes are shown. n=3/genotype, *p<0.05 by ANOVA with Bonferroni 
correction. 
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Figure 4 
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Figure 4. Competitive repopulation. Mobilized donor cells (CD45.2+) are 
collected from the PB following mobilization and transplanted along with BoyJ 
competitor BMC (CD45.1+) into lethally irradiated recipients. The percentage of 
donor-derived cells in the PB was measured monthly. 
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Lethally irradiated recipients received mobilized peripheral blood cells 
from donor mice (CD45.2+) along with Boy J (CD45.1+) competitor BMC. The 
amount of competitor cells transplanted was sufficient to rescue lethally irradiated 
recipients approximately 30% of the time, any survival higher than this can be 
attributed to rescue from the donor cell population. For the Fanca-/- and Fancc-/- 
genotypes, there was a significant increase in survival when both G-CSF and 
AMD3100 were used to mobilize the transplanted cells as compared to either 
agent alone (Figure 5). 
CD45.1 and CD45.2 chimerism was analyzed monthly in order to 
determine the competitive repopulating ability of mobilized test cells. The 
repopulating ability of fresh BMC from the three respective genotypes was also 
calculated (Figure 6 and Table I). As expected, the repopulating ability of the 
BMC from Fanca-/- and Fancc-/- mice was only 35-40% of syngeneic WT 
controls (Table I). Strikingly, there was a much greater defect in the repopulating 
activity of Fanca-/- and Fancc-/- PB cells following mobilization with G-CSF alone 
(15-30% of WT controls) analogous to the paucity of CD34+ phenotypic cells 
mobilized using G-CSF only in FA patients (Croop, Cooper et al. 2001) and the 
reduced numbers of lineage restricted and multipotent progenitors. 
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Figure 5. Transplantation with HSC/HPC mobilized by both AMD3100 and 
G-CSF resulted in an increase in survival. Transplantation with HSC/HPC 
mobilized by both AMD3100 and G-CSF resulted in an increased survival over 
time as compared to either AMD3100 alone or PBS for each respective genotype 
by log-rank test for trend. n=8, *p<0.05. 
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Figure 6 
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Figure 6. Mobilization of HSC is enhanced when G-CSF and AMD3100 are 
used in combination. Flow cytometry analysis was used to determine 
percentage of donor-derived chimerism in the PB of recipient mice (A). Mean 
percent donor cell chimerism of each genotype and mobilization group are 
indicated (B-D). Use of both AMD3100 and G-CSF resulted in a significant 
increase in chimerism as compared to either agent alone for all genotypes at all 
time points. Results are shown as mean ± SEM. n=5; *p<0.05 by ANOVA. (E) 
Secondary transplantations showed no significant change in chimerism, implying 
the mobilized cells had self-renewal capacity. Results depict mean chimerism 4 
months post transplantation for primary recipients (white bars) receiving G-CSF 
plus AMD3100 mobilized cells and mean chimerism 4 months post 
transplantation for secondary recipients (black bars). n=3 for primary recipients, 
n=6 for secondary recipients, mean ± SEM, p>0.05.  
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Table I. Repopulating units of bone marrow and mobilized cells from WT, 
Fanca-/- and Fancc-/- mice. 
 BM RU/1 ml PB 
 RU/Femur G-CSF AMD3100 
G-CSF & 
AMD3100 
WT 72.30±0.17 4.12±0.89 1.90±0.62 10.66±0.58 
Fanca-/- 25.29±0.06 0.67±0.03 0.51±0.13   2.57±0.12 
Fancc-/- 26.02±0.10 1.23±0.57 0.47±0.12   3.21±0.32 
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Though stem cells mobilized with AMD3100 alone resulted in low 
chimerism in all experimental groups (Figure 6B-D), addition of G-CSF to 
AMD3100 resulted in a greater than additive increase in the chimerism and 
repopulating ability of Fanca-/- and Fancc-/- HSC (Figure 6C-D, Table I). 
To verify that repopulating HSC with self-renewal capacity were mobilized 
to PB, primary recipients were sacrificed four months following transplantation 
and bone marrow LDMC from these recipients were transplanted into lethally 
irradiated secondary recipients. No significant change in chimerism occurred 
following transplantation into secondary recipients (Figure 6E). To determine 
whether the donor cells contributed to multiple blood lineages, multi-color flow 
cytometry was performed. Analysis of CD45.2+ PB cells with B220, CD3, Gr-1 
and Mac-1 antibodies demonstrated the presence of multi-lineage lymphoid and 
myeloid derived CD45.2+ donor cells. An analysis from a representative recipient 
is shown in Figure 7 and the data is summarized in Table II. Collectively, the 
results support the hypothesis that AMD3100 plus G-CSF resulted in mobilization 
of long-term, multi-lineage, self-renewing HSC. 
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Figure 7. G-CSF plus AMD3100 mobilized HSC are capable of sustaining 
multi-lineage reconstitution. CD45.2+ PB cells from primary recipients 
receiving WT, Fanca-/- or Fancc-/- HSC mobilized with G-CSF and AMD3100 
were analyzed for CD3, B220, Gr-1 and Mac-1 expression. Results depicted 
above are representative samples gated on CD45.2+ in order to show the 
percentage of CD45.2+ PB cells expressing the respective antigen. 
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Table II. Multi-lineage differentiation of AMD3100 and G-CSF mobilized PB 
cells in recipient mice. CD45.2+ PB cells from primary recipients receiving 
either WT, Fanca-/- or Fancc-/- mobilized HSC were analyzed for CD3, B220, Gr-
1 and Mac-1 expression 4 months post transplantation. Results depicted are 
mean percentages of chimeric CD45.2+ PB cells expressing the respective 
antigen ± SEM. n=5. 
 
  CD3 B220 GR-1 MAC-1 
WT 21 ± 6 24 ± 7 31 ± 7 24 ± 7 
Fanca-/- 26 ± 4 22 ± 6 21 ± 6 30 ± 5 
Fancc-/- 29 ± 4 34 ± 3 16 ± 5 30 ± 6 
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FA remains a complex genetic disorder with significant morbidity and 
mortality (Kutler, Singh et al. 2003) and few treatment options (Gluckman, 
Auerbach et al. 1995). There is a great need to develop other treatments. 
Genetic correction and transplantation of autologous HSC is a potential therapy; 
however, mobilization of adequate HSC in FA patients is a key prerequisite for 
non-invasive collection. Previous trials in FA patients using extended G-CSF 
administration mobilized a limited number of CD34+ cells (Croop, Cooper et al. 
2001). Whether the relative inability of G-CSF to mobilize CD34+ cells in FA 
patients is a consequence of bone marrow hypoplasia or a defect in stem 
cell/stromal cell interactions is unclear. This question is difficult to address in 
human patients; however, the availability of syngeneic FA knockout mice 
provided the opportunity to address this issue in a preclinical setting. 
Discussion 
Here, the repopulating ability was quantitatively examined for the bone 
marrow and the mobilized PB HSC in syngeneic FA and WT mice. As expected 
from previous studies (Carreau, Gan et al. 1999; Haneline, Gobbett et al. 1999; 
Si, Ciccone et al. 2006), both Fanca-/- and Fancc-/- mice had a significant 
decrease in bone marrow repopulating ability as compared to the repopulating 
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ability of WT mice. However, in response to G-CSF alone, this decrease in 
repopulating ability was accompanied by an additional decrease in the proportion 
of repopulating units mobilized from the bone marrow to the peripheral blood. 
Our results demonstrate that mobilization with both AMD3100 and G-CSF results 
in a synergistic increase in the mobilization of long-term, multi-potential, self-
renewing HSC. These studies did not directly compare the repopulating ability 
when equal numbers of mobilized cells were transplanted from the different 
treatment groups. This experiment would be an interesting future direction to 
determine if the mobilized FA cells have an engraftment and repopulation 
advantage as compared to FA BMC as has been shown for normal mobilized 
cells (Nademanee, Sniecinski et al. 1994; Schmitz, Linch et al. 1996; Champlin, 
Schmitz et al. 2000). Additionally, in the Fancc-/- cells the multi-lineage analysis 
showed a lymphoid bias that is sometimes associated with aging (Gruver, 
Hudson et al. 2007; Miller and Cancro 2007). It is now necessary to address the 
potential of these mobilized cells as targets for gene transfer in FA murine 
models and in human NOD-SCID repopulating cells. 
Data from this study demonstrate that mobilization of PB repopulating 
stem cells with G-CSF is clearly defective in FA knockout mice. One possibility is 
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that FA deficient HSC have an inability to respond to a number of chemokines 
that are important for stem cell mobilization. However, in preliminary studies, the 
responsiveness of myeloid progenitors to a number of cytokines and chemokines 
(including stem cell factor, G-CSF and stromal cell-derived factor-1) did not 
display such a phenotype (unpublished data, 2007). Alternatively, recent data 
show that HSC/HPC mobilization is dependent on a complex model involving 
both protease dependent and independent mechanisms (Robinson, Pisarev et al. 
2003; Levesque, Liu et al. 2004; Pelus, Bian et al. 2004; Robinson, Seina et al. 
2005; Lee, Wu et al. 2009; Jalili, Shirvaikar et al. 2010). Given our observations 
in these studies and the fidelity with which the murine models recapitulate the 
human mobilization defects, the FA murine models used here may be useful in 
future studies to discern the basic mechanisms underlying this clinical 
phenotype. 
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CHAPTER 4 
Overnight transduction with FV vector containing the FANCC gene restores the 
long-term repopulating activity of mobilized Fancc-/- cells 
 
Spontaneous genetic correction of a germline mutation leading to 
repopulation of the entire hematopoietic system with normal progeny has been 
identified in a few FA patients (Waisfisz, Morgan et al. 1999; Gregory, Wagner et 
al. 2001; Gross, Hanenberg et al. 2002; Soulier, Leblanc et al. 2005; Mankad, 
Taniguchi et al. 2006). Additionally, in mice with targeted disruptions of FA 
genes, the hematopoietic system can be functionally corrected by retroviral 
vectors expressing human analogues of the targeted mouse genes in stem cells 
(Gush, Fu et al. 2000; Galimi, Noll et al. 2002; Haneline, Li et al. 2003). These 
observations have led to three clinical stem cell gene therapy phase I studies in 
FANCA-/- and FANCC-/- patients. So far, neither long-term marking/correction of 
cells nor clinical benefits for the patients were observed (Liu, Young et al. 1997; 
Kelly, Radtke et al. 2007). Due to the biological characteristics of the 
gammaretroviral vectors used for transduction of stem cells (Roe, Reynolds et al. 
Introduction 
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1993; Trobridge and Russell 2004), optimal gene transfer protocols for delivery of 
genes to mammalian stem cells require a pre-stimulation period of 1-2 days with 
cytokines that promote the proliferation and survival of stem/progenitor cells. This 
is followed by a 2-3 day exposure of the target cells to vector containing 
supernatant on the recombinant fibronectin fragment CH-296 (Hanenberg, Xiao 
et al. 1996; Hanenberg, Hashino et al. 1997). This gene transfer protocol was 
successful in transducing hematopoietic stem cells in humans, primates/monkeys 
and mice (Cavazzana-Calvo, Lagresle et al. 2005; Macchiarini, Manz et al. 2005; 
Trobridge, Beard et al. 2005). However, in murine FA models, prolonged in vitro 
culture of Fancc-/- bone marrow results in a length-of-culture dependent 
reduction in myeloid progenitors and repopulating ability (Haneline, Gobbett et al. 
1999; Li, Le Beau et al. 2005), and the surviving untransduced Fancc-/- 
repopulating cells have an increased risk of developing cytogenetic abnormalities 
and myeloid malignancies (Haneline, Li et al. 2003). Therefore, limiting the in 
vitro culture would be predicted to both enhance the efficacy and the safety for 
genetic therapies of FA stem cells. 
Our lab has previously demonstrated the ability of FV vectors encoding 
the human FANCC transgene to completely correct murine Fancc-/- myeloid 
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progenitors and repopulating hematopoietic stem cells in a 14-hour transduction 
protocol without prestimulation. This short gene transfer protocol resulted in 1-2 
proviral integrations in the reconstituting stem cells and was not associated with 
the development of myelodysplastic syndromes (MDS) or acute myeloid 
leukemia (AML) in Fancc-/- stem cells transduced with the reporter construct (Si, 
Pulliam et al. 2008). These characteristics support the hypothesis that FV vectors 
are a viable strategy for stem cell gene transfer strategies in FA. 
However, very little research has been done on the ability of FV to 
transduce mobilized HSC (Josephson, Vassilopoulos et al. 2002; Kiem, Allen et 
al. 2007). There is evidence that the mobilized cell population does not respond 
to transduction in the same manner as the BMC population (Hematti, Sellers et 
al. 2003; Thomasson, Peterson et al. 2003), perhaps due to mobilization’s effects 
on cell surface receptors or other biochemical changes in the cells. Therefore, 
the transduction of mobilized HSC/HPC in our murine model has been studied. 
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Our lab has previously developed a FV construct (Si, Pulliam et al. 2008) 
derived from the pMD9 construct, a gift from Axel Rethwilm (Würzburg, 
Germany). In our construct, the coding capabilities of all of the FV genes and the 
enhancer elements have been eliminated by complete or partial deletions. There 
is a remaining non-coding 5’ region of GAG and 3’ region of POL, which retain 
the packaging signals (CAS I and II) that are essential for the production of the 
FV particles. The encephylomyelocarditis (EMCV) internal ribosome entry site 
(IRES) and the enhanced green fluorescence protein (EGFP) cDNAs were 
cloned into the construct (MD9-EGFP) (Figure 8). The hFANCC cDNA was 
cloned into the MD9-EGFP construct under the spleen focus forming virus 
(SFFV) promoter (MD9-FANCC/EGFP) (Figure 8).  
Results 
These plasmid constructs are transfected using polyethylenimine into 
293T cells along with the helper plasmids: pcoPOL, pcoGAG and pcoPE01; 
which provide the coding sequences for the polymerase, structural and envelope 
proteins respectively.  
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 Figure 8 
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Figure 8. Structure of the recombinant FV self-inactivating vectors MD9-
FANCC/EGFP and MD9-EGFP. These vectors contain deletions in gag, pol, env 
and the U3 region of the 3’ LTR. SFFV U3 is the promoter of the spleen focus-
forming virus U3 region driving the human FANCC and the EGFP cDNAs (Si, 
Pulliam et al. 2008). 
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None of the helper plasmids contain the packaging sequences, therefore 
only the MD9-EGFP or MD9-FANCC/EGFP construct RNA should be packaged 
into the FV virions. This, along with the deletion of the Tas transactivator, means 
that the virions should be replication incompetent.  
The supernatant is collected, filtered, concentrated and either used fresh 
or frozen. For these experiments an MOI of 10 was used. The separation of the 
POL/GAG onto two separate plasmids and the isolation and cloning of a new 
envelope (pcoPE01) by our collaborator, Dr. Helmut Hanenberg are changes 
from our previous work (Si, Pulliam et al. 2008). 
Our results show that the mobilized Fancc-/- cells transduced with the 
reporter construct had a significantly decreased number of progenitors as 
compared to the Fancc-/- cells corrected with the transgene (Figure 9). 
Additionally, the colony forming ability was corrected to levels comparable to WT 
(Figure 9). While this seems very promising, from this experiment the 
transduction efficiency was not determined. However, a portion of these cells 
was used for the following competitive repopulation experiments and post-
transplantation assays were used to determine the transduction efficiency. 
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Figure 9. Correction of G-CSF and AMD3100 mobilized Fancc-/- LDMC 
results in a significant increase in progenitors/1ml PB. n=3, plated in 
triplicate. *p<0.01 by student’s t-test. 
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Competitive repopulation is a very sensitive measure of the capabilities of 
a cell to repopulate a lethally irradiated recipient. Because the donor cells are 
competing against competitor cells from the same pool, chimerism levels can be 
compared as a measure of competitive repopulating ability. Here, competitive 
repopulation experiments were performed to determine the repopulating ability of 
the mobilized transduced cells.  
A significant increase was observed in the Fancc-/- cells corrected with 
the FANCC transgene as compared to those transduced with only MD9-EGFP 
(Figure 10). The increase in competitive repopulating ability for the Fancc-/- cells 
corrected with the FANCC transgene resulted in a chimerism level comparable to 
WT (Figure 10). From the peripheral blood a very low expression of EGFP was 
observed. This is as anticipated and has been observed many times with this 
construct (Si, Pulliam et al. 2008). Because the competitive repopulation assay 
shows a correction in the function of the HSC/HPC, it is believed that the 
construct is present and the expression of the EGFP has decreased because it is 
the second gene expressed from the construct. To further confirm this, the viral 
construct DNA was detected as an indicator of transduction.  
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Figure 10 
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Figure 10. Correction of Fancc-/- mobilized cells results in a significant 
increase in repopulating ability to levels comparable to WT. n=7 per group, 
*p<0.05 by student’s t-test as compared to Fancc-/- with EGFP at the respective 
time point. There was not a statistically significant decrease in WT chimerism 
from 12 weeks to 18 weeks post transplantation (n=7, p>0.05 by student’s t-test). 
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Four months post transplantation the LDMC from the bone marrow of a 
portion of these primary recipients was collected and sorted for the donor cells. 
These cells were plated in standard clonogenic assays. In order to be certain that 
the CD45.2+ chimerism observed was due to test cell repopulation and not 
endogenous recipient mouse cell repopulation, colonies were picked from these 
assays and genotyping was done to confirm that the CD45.2+ cells were indeed 
from the donor Fancc-/- transduced cells (Figure 11A). Representative samples 
are shown. In the results from 50 colonies from 5 different mice 82% were the 
correct genotype.  
A PCR for the EGFP portion of the proviral integrant was performed to 
determine the percentage of colonies that were positive for the transgene. 
Representative samples are shown in Figure 11B and summary data is shown in 
Table II. 91% of colonies from mice transplanted with Fancc-/- cells transduced 
with MD9-FANCC/EGFP were positive for EGFP. Those Fancc-/- or WT cells 
transduced with the reporter construct only had lower percentages of colonies 
positive for the transgene. This is expected because the reporter construct does 
not confer a survival advantage.  
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Figure 11 
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Figure 11. Analysis of genotype and transduction efficiency of myeloid 
progenitors. CD45.2+ BMC were sorted and cultured in semisolid medium to 
grow myeloid progenitors. DNA from individual colonies was isolated and 
amplified to detect the genotype (A) and presence of the provirus (B). 
Representative gels of the amplified PCR products are shown. The test cell 
genotype and the provirus utilized are indicated. 
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Sensitivity to MMC and TNF-α is one characteristic of Fancc-/- cells. The 
colony assays assessing the CD45.2+ cells from the bone marrow of primary 
recipients after 4 months also included conditions with varying concentrations of 
MMC and TNF-α to determine the sensitivity of the cells. The Fancc-/- cells 
corrected with the transgene demonstrated WT levels of resistance, this implies 
that after 4 months in vivo the transgene is still being expressed and the protein 
is functioning in the FA pathway.  
An equally important point is that the Fancc-/- cells transduced with the 
reporter construct only were still sensitive to these agents (Figure 12). The 
retroviral constructs used previously have resulted in myeloid malignancies that 
can be detected by a decrease in sensitivity to these agents (Haneline, Li et al. 
2003), although the recipients will need to be assessed after a longer in vivo 
period to compare directly with the retroviral data, it is still promising to see that 
at this time point there is no decrease in sensitivity. Because it is very likely that 
not all of the transplanted cells will be transduced, it is especially important to 
perform this control to assess the non-corrected cells likelihood of developing 
myeloid malignancies. 
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Figure 12. MMC and TNF-α hypersensitivity is maintained in primary 
recipients of MD9-EGFP transduced Fancc-/- cells 4.5 months after 
transplantation. Bone marrow LDMC from Fancc-/- with MD9-EGFP (n=6), 
Fancc-/- with MD9-FC/EGFP (n=6) and WT MD9-EGFP (n=5) recipients were 
cultured in clonogenic assays in triplicate to determine their respective sensitivity 
to MMC or TNF-α at 18 weeks following transplantation. The genotypes and viral 
transgenes are indicated. Data represent the mean ± SEM growth of all 
recipients in each respective group. *p<0.05 indicates statistical significance 
between the non-corrected Fancc-/- cells and the other two experimental groups 
by ANOVA.  
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Junctional fragment analysis using southern blot was performed from the 
whole bone marrow and spleen and only 1 integration site was detected in each 
of 3 mice examined (data not shown). One explanation for this is the low MOI 
used. Also, multiple integration sites may result in apoptosis of the cells. Further 
integration site analysis will be beneficial in future experiments. 
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Currently, the best method to treat BMF in FA patients is the 
transplantation of normal HSC, (Gluckman, Broxmeyer et al. 1989; Davies, Khan 
et al. 1996; Guardiola, Pasquini et al. 2000; Kutler, Singh et al. 2003; Wagner, 
Eapen et al. 2007). However, allogeneic bone marrow or cord blood 
transplantation is not without subsequent risk as the conditioning regimens cause 
genotoxic stress that predisposes patients to an increased incidence of 
squamous cell carcinomas especially when compounded by the presence of 
chronic graft-versus-host disease (Kutler, Auerbach et al. 2003; Rosenberg, 
Socie et al. 2005). Thus, the transduction of autologous, genetically corrected 
stem cells in the absence of genotoxic myelopreparation could provide a therapy 
that does not expose the patient to these potential sequelae (Si, Ciccone et al. 
2006).  
Discussion 
Natural reversions of inherited germ-line mutations seen in a small 
population of FA patients strongly suggest that an oligoclonal population or 
perhaps a single hematopoietic stem cell is sufficient to correct the hematopoietic 
system (Waisfisz, Morgan et al. 1999; Gregory, Wagner et al. 2001; Gross, 
Hanenberg et al. 2002; Soulier, Leblanc et al. 2005; Mankad, Taniguchi et al. 
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2006). Unfortunately, long-term multipotential cell transduction leading to 
hematologic improvement in the patient has not been observed with 
gammaretroviruses in FA clinical trials to date (Liu, Young et al. 1997; Kelly, 
Radtke et al. 2007). One possible reason for this failure of genetic therapy is the 
low number of stem cell targets available for gene transfer (Williams, Croop et al. 
2005). In addition, even in the presence of saturating concentrations of growth 
factors, FA cells have an increased propensity to undergo apoptosis (Li, Le Beau 
et al. 2005). Therefore, the prolonged culture required to induce stem cells into 
cycle and allow gammaretroviruses to integrate into the target cell genome 
predisposes untransduced FA stem cells to undergo apoptosis (Li, Le Beau et al. 
2005). 
In studies here, FV vectors expressing the human FANCC cDNA 
functionally corrected multiple defects in mobilized Fancc-/- stem cells capable of 
repopulating primary recipients. Due to their specific biology, the use of FV 
vectors can theoretically address several problems associated with somatic stem 
cell gene therapy in FA. As mentioned previously, FV is not associated with any 
disease in humans (Switzer, Bhullar et al. 2004). Also, in contrast to gamma-
retroviruses that have a half-life of only 4-6 hrs in vivo (Andreadis, Brott et al. 
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1997), non-integrated FV virions retain the potential for stable integration in 
quiescent cells for up to 2 weeks following transduction (Lehmann-Che, Renault 
et al. 2007). Thus, cells only need to be exposed in vitro to virions for a short time 
allowing cycling of the target cells and proviral integration to occur in vivo. As 
mentioned previously, since FA murine and human FA stem cells have increased 
in vitro time dependent induction of apoptosis and at least Fancc-/- cells develop 
in vitro dependent clonal transformation (Haneline, Li et al. 2003; Li, Le Beau et 
al. 2005), this abbreviated transduction protocol efficiently corrects FA stem cells 
(Si, Pulliam et al. 2008). Also, in vitro manipulation of mobilized Fancc-/- LDMC 
for 14 hrs in the absence of prestimulation, as presented here, is sufficient for 
FV-mediated delivery of FANCC to cells and correction of long-term repopulating 
activity in primary transplantations.  
One or two proviral integrations were observed in the bone marrow and 
spleen cells of reconstituted mice in these experiments as well as previous 
experiments (Si, Pulliam et al. 2008). There are at least three possibilities for this 
observation. One possibility is that analogous to rare cases of apparently 
spontaneous correction of FA stem cells (Waisfisz, Morgan et al. 1999; Gregory, 
Wagner et al. 2001; Gross, Hanenberg et al. 2002; Soulier, Leblanc et al. 2005; 
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Mankad, Taniguchi et al. 2006), correction of a subpopulation of Fancc-/- cells 
with a functional transgene leads to an in vivo selection of the corrected cells. 
Future studies mixing ratios of transduced and untransduced cells into irradiated 
recipients may allow formal testing of this hypothesis. Alternatively, previous 
studies have shown that hematopoiesis in reconstituted lethally irradiated mice 
tends to be oligoclonal in nature (Jordan and Lemischka 1990; Jordan, McKearn 
et al. 1990). This correlates with our previously published data (performed with 
an MOI of 20 as compared to the MOI of 10 used here), which show a low 
number of integrants, regardless of the transgene or stem cell genotype (Si, 
Pulliam et al. 2008). In contrast to our studies in mice, a recent report using 
foamy viral vectors to treat canine leukocyte adhesion deficiency (CLAD) found 
multiple integrants in this large animal model (Bauer, Allen et al. 2008). A third 
possibility necessary to consider is that of clonal selection leading to MDS. In 
previous studies clonal selection was tested for extensively. The hematopoietic 
organs and clonogenic growth from the myeloid progenitors of primary and 
secondary recipients were examined over a total of 18 months. From multiple 
recipients, no pathological abnormalities were observed. Additionally, in these 
studies no pathological abnormalities were observed in the recipient mice (Si, 
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Pulliam et al. 2008). The lack of pathological sequelae is consistent with the 
study in CLAD dogs where FV integrations were found within genes or near 
oncogenes at a much lower frequency than as reported for retroviral vectors 
(Bauer, Allen et al. 2008). 
A potential limitation to the use of FV vectors in the clinic to date is that the 
fusogenic capacities of FV envelope proteins (Stanke, Stange et al. 2005; Duda, 
Luftenegger et al. 2006), especially when cells are exposed to higher virus titers 
and for prolonged periods of time. The envelope used here, pcoPEO1, has not 
caused fusion of the hematopoietic target cells in these studies.  
Collectively, these studies demonstrate that the functional expression of a 
transgene using a FV construct can cure a disease phenotype in a murine model 
of a human disease with cells collected in a manor similar to that used in 
patients. With some additional modifications this gene delivery system may be 
applicable for therapeutic use in humans. 
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CHAPTER 5 
Genetic disruption of both Fancc and Fancg in mice recapitulates the 
hematopoietic manifestations of Fanconi anemia 
 
As mentioned previously, FA patients develop progressive BMF, ultimately 
requiring stem cell transplantation in the second or third decade of life 
(Gluckman, Auerbach et al. 1995). The progressive BMF can also lead to 
hematologic neoplasms, particularly MDS and AML (Gluckman, Auerbach et al. 
1995; Alter, Greene et al. 2003; Kutler, Singh et al. 2003), both of which are 
almost universally associated with aneuploidy and cytogenetic abnormalities 
(Auerbach and Allen 1991; Tonnies, Huber et al. 2003). The interactions among 
the FA proteins are complex and incompletely understood. While certain FA 
proteins function in the core complex as described above, additional functions 
have been described for individual FA proteins suggesting a critical role in 
maintenance of normal hematopoiesis (Pang, Christianson et al. 2001; Pang, 
Christianson et al. 2002; Zhang, Li et al. 2004; Gordon, Alon et al. 2005; 
Hussain, Wilson et al. 2006; Leveille, Ferrer et al. 2006; Mukhopadhyay, Leung 
Introduction 
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et al. 2006; Wilson, Yamamoto et al. 2008), yet these mechanisms have not 
been evaluated using a genetic model. Murine knockouts of the homologues of 
FANCA (Fanca), FANCC (Fancc), FANCG (Fancg), FANCD1 (FancD1), 
FANCD2 (Fancd2) and FANCM (Fancm) have been established (Bakker, van de 
Vrugt et al. 2009; Parmar, D'Andrea et al. 2009). Although all strains of FA 
knockout mice are hypersensitive to MMC, none of these single knockout mice 
display spontaneous aplastic anemia or myeloid malignancies characteristic of 
FA in patients (Bakker, van de Vrugt et al. 2009; Parmar, D'Andrea et al. 2009). If 
FA proteins have divergent functions independent of ID complex 
monoubiquitination in hematopoietic cells, double knockout mice might display a 
more aggressive hematopoietic phenotype. Therefore, Fancc-/-;Fancg-/- mice 
were generated and these results show that these mice more faithfully 
recapitulate the hematological manifestations observed in FA patients. 
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In initial experiments in the lab (performed by Dr. Samantha Ciccone), 
multipotent, erythroid and myeloid progenitors from syngeneic 3-month-old WT, 
Fancc-/- and Fancg-/- mice were found to have differences in clonogenic 
potential (Figure 13A-D). These functional results provided the first suggestion 
that FANCC and FANCG have non-overlapping roles in hematopoiesis.  
Results 
To further evaluate this possibility, microarrays were conducted to test the 
hypothesis that loss of both Fancc and Fancg will result in a significant change in 
the expression profile (Figure 13E-G). To accomplish this, unsupervised 
hierarchical clustering and principal component analyses were performed on 
expression microarray data from BMC RNA from 3-month-old syngeneic mice: 
WT, Fancc-/-, Fancg-/- and double knockout Fancc-/-;Fancg-/- mice. The results 
demonstrated that double mutant cells diverged more widely from the WT cells 
than did either of the single mutants (Figure 13E-F). Hence, there were more 
commonalities found in the expression space between the two single mutants 
and also between them and the WT samples; but significantly greater 
dissimilarities between these three groups and the double mutant samples 
(Figure 13E-F).  
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Figure 13 
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Figure 13. Loss of Fancg results in a more severe defect in multiple 
hematopoietic compartments than loss of Fancc. (A) Total number of 
progenitors per femur isolated from syngeneic 3-month-old mice with statistically 
similar weights (25 ± 0.6g) and bone marrow cellularity (10 X 106 ± 0.7 X 106 cells 
per femur). *p=0.0009 by one-way ANOVA. (B) Number of multipotential Colony 
Forming Unit-Granulocyte, Erythrocyte, Monocyte, Megakaryocyte progenitors 
(CFU-GEMM), *p<0.0001 by one-way ANOVA. (C) Colony Forming Unit-
Granulocyte-Macrophage progenitors (CFU-GM), *p=0.0230 by one-way 
ANOVA. (D) Burst Forming Unit-Erythroid progenitors (BFU-E), *p=0.0030 by 
one-way ANOVA. Data represent mean ± SEM of 3 independent experiments 
each of which was plated in triplicate cultures. (E and F) Genome-wide 
transcriptomal analysis of marrow cells from 3-month-old mice from each of the 
four indicated FA genotypes was performed. A total of 12 BMC samples from 12 
mice (Fancc-/-;Fancg-/-, Fancc-/-, Fancg-/- and WT) were analyzed using 12 
AffyMetrix MOE 430 2.0 GeneChip arrays. (E) Unsupervised hierarchical 
clustering, the scale represents the level of correlation between the groups. (F) 
Principal component analysis. In this case the multidimensional data were 
reduced to a new coordinate system such that the greatest variance (20.8%) by 
any possible projection of the data is plotted on the first coordinate (the first 
principal component, PCA1). The second greatest variance (14.5%) was plotted 
on the second coordinate (PCA2) and the third greatest (10.8%) plotted on the 
third coordinate (PCA3). Results from both analyses confirmed that double 
mutant cells diverged widely from both the WT samples and both of the single 
mutant samples. 
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A Venn diagram provides a visual representation of the differential gene 
expression by each genotype (Figure 13G), providing evidence that each strain 
has uniquely expressed genes. The differences did not include variations in 
lineage specific gene expression (Table III) assuring that the biological 
differences observed (see below) did not derive from modest differences in the 
populations present in the bone marrow of the animals. 
Since the hallmark of FA cells is hypersensitivity to DNA cross-linking 
agents, the growth of hematopoietic progenitors from single and double mutant 
3-month-old FA mice and syngeneic WT control mice in the presence of MMC 
was evaluated (Dr. Samantha Ciccone) (Figure 14A). The progenitors from 
Fancc-/-, Fancg-/- or Fancc-/-;Fancg-/- mice had comparable hypersensitivity to 
MMC (Figure 14A).  
To further evaluate abnormalities in the hematopoietic compartment, 
cohorts of WT, Fancc-/-, Fancg-/- and Fancc-/-;Fancg-/- mice were observed up 
to 24 months. These mice were sacrificed and evaluated when they developed 
signs of illness. A significant decrease in survival of Fancc-/-;Fancg-/- mice was 
observed as compared to other genotypes (Figure 14B).  
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Table III. Expression of genes relevant to lineage specific differentiation. 
Expression of genes relevant to lineage specific differentiation did not differ 
between Fancc-/- (n=3), Fancg-/- (n=3) and double Fancc-/-;Fancg-/- (n=3) mice. 
The genes listed in column 2 were not differentially expressed when gene 
expression profiles of the three strains were compared using GeneSifter 
(Geospiza, Seattle, WA). 
 
Lineage Genes Expressed 
Erythroid Sfp1, Ank1, Epb4.2, Hba1, Hbb-b1,Eraf1, Spna1 
Granulocytes Cbfa2t3, Sfp1, Ltf, Mpo, Cd11b, Cd15, Csf3r 
Eosinophils Il-25, Il5ra 
Monocytes/Macrophages SpiB, Lif, Cd14 
Megakaryocytes Sp3, Tesc, mpl 
T-cells Tcf7, CD3, CD4, CD8 
B-cells Cd19, Cd20, Cd1d, Rag1, Vpreb1 
NK-cells Il-21, Il-11R, Ikzf1, Stat5b 
Lymphoid (general) IL2rg, Il-7ra, Nfkbid, Syk, Lef1, Il-4r, Il-6, Il-20r, Il-12b, 
Cd40 
Unlimited (relevant 
to hematopoiesis) 
c-kit, Flt1, Flt2, Flt3, Xrcc5, Ercc2, Sox4, Xrcc4, Tal1, 
Meis1, Irf4, Egr1, Wisp1, CD28, Foxp1, Cd79, Cd79a, 
Inpp5d,Thpo, Csf2, Csf3 
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Figure 14 
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Figure 14. Fancc-/-;Fancg-/- mice have a shortened life span and an 
increased risk of BMF despite similar MMC sensitivity of Fancc-/-, Fancg-/- 
and Fancc-/-;Fancg-/- cells. (A) Sensitivity of WT, Fancc-/-, Fancg-/- and 
Fancc-/-;Fancg-/- cells to MMC. Data represent mean ± SEM of 3 independent 
experiments each of which was plated in triplicate cultures isolated from the bone 
marrow of 3-month-old syngeneic mice. WT is significantly different than any of 
the other experimental groups, which had comparable sensitivity, *p<0.001 by 
two-way ANOVA. (B) Kaplan-Meier curve shows a significant decrease in 
survival of Fancc-/-;Fancg-/- mice compared to WT, Fancc-/- or Fancg-/- mice, 
n=8/genotype *p=0.0004 for Fancc-/-;Fancg-/- as compared to WT, Fancc-/- or 
Fancg-/- by the log rank test for trend. (C) Fancc-/-;Fancg-/- mice, but not WT, 
Fancc-/- or Fancg-/- mice, develop aplastic anemia and myeloid malignancies. 
Panels 4 and 9 are from a 20-month-old Fancc-/-;Fancg-/- mouse and panels 5 
and 10 are from a 23-month-old Fancc-/-;Fancg-/- mouse. 
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In order to determine the cause of the increased mortality in these mice, 
serial evaluations of complete peripheral blood counts of primary Fancc-/-;Fancg-
/- mice were performed. At the time of death or sacrifice due to illness, 50% of 
double knockout mice had a moderate leukocytosis (white blood cell counts 
>15.9K/µl), dysplastic megakaryocytes, a myeloid maturation arrest and 
splenomegaly (>200mg) with an invasion of myeloid cells leading to a disruption 
of normal splenic architecture (Figure 14C, representative samples). Another 
25% of the Fancc-/-;Fancg-/- mice had anemia (hemoglobin level <7.0g/dL), 
decreased bone marrow cellularity (<50% of WT) and hypoplastic marrow 
containing large numbers of adipocytes (Figure 14C, representative samples). 
The remaining mice did not have signs of illness at 24 months of age.  
Our lab also examined the phenotype of the Fancc-/-;Fancg-/- 
hematopoietic stem cells in greater detail by utilizing a competitive repopulation 
assay. In this assay, stem cell activity is quantified by comparing the ability of 
mutant and WT BMC to establish long-term hematopoiesis in competition with 
isogenic WT cells (Abramson, Miller et al. 1977; Harrison 1980; Jordan and 
Lemischka 1990). Upon transplantation of mixed test and competitor cells (two 
cohorts were performed, one with a ratio of 5:1(shown), one with a ratio of 3:1) 
 96 
into lethally irradiated recipients, PB chimerism was assessed monthly for 1 year 
by flow cytometry to determine test cell contribution to hematopoiesis (Figure 15) 
(transplantations and chimerism performed by Dr. Samantha Ciccone, 
histological analysis performed by Anna C. Leath). The test cell repopulating 
activity was decreased in recipients reconstituted with either Fancc-/- or Fancg-/- 
BMC as compared to WT BMC (Figure 15B).  
Interestingly, the peripheral blood chimerism of recipients reconstituted 
with Fancc-/-;Fancg-/- BMC showed widely variable chimerism over time (Figure 
15B, 16A) in contrast to stable chimerism in recipients reconstituted with all the 
other test cell genotypes (Figure 15B). The Fancc-/-;Fancg-/- chimerism data is 
shown in Figure 15B to allow for comparison with the other genotypes and then 
again in Figure 16A which shows the change in chimerism of each individual 
recipient mouse. In some Fancc-/-;Fancg-/- BMC recipients, the test cell 
population progressively out-competed the competitor cells while in other 
recipients the repopulating activity of the test cells was progressively reduced 
(Figure 16A).  
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Figure 15. Fancc-/-;Fancg-/- hematopoietic stem cells undergo clonal 
evolution and malignant transformation in vivo. (A) Experimental design: 
Test BMC and isogenic WT competitor cells were co-transplanted into lethally 
irradiated recipient mice at a 5:1 ratio (2.5 X 106 test cells and 0.5 X 106 
competitor cells). (B) The contribution of transplanted test cells to hematopoiesis 
was sequentially monitored in the peripheral blood of individual mice. Fancc-/- 
and Fancg-/- stem cells establish hematopoiesis less efficiently than WT 
hematopoietic stem cells. Increasing variability was observed in the peripheral 
blood chimerism in mice transplanted with Fancc-/-;Fancg-/- BMC, but not Fancc-
/-, Fancg-/- or WT BMC. There was significant increase in the variability of 
chimerism in recipients receiving the Fancc-/-;Fancg-/- cells when comparing 4 
months to 12 months, ANOVA with Bartlett’s test to compare variances, 
*p=0.0149. (C) Mice reconstituted with BMC from Fancc-/-;Fancg-/- mice showed 
abnormal bone marrow and spleen architecture 12 months post-transplantation. 
Panels 1 and 3 are from mouse 5 in Figure 16A, with a chimerism of 38% at 12 
months post-transplantation. Panels 2, 4 and 5 are from mouse 2 in Figure 16A. 
Panel 5 shows megakaryocyte invasion in the spleen.
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Figure 16 
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Figure 16. Fancc-/-;Fancg-/- hematopoietic stem cells have malignant 
potential in vivo, while Fancc-/- or Fancg-/- cells do not. (A) Fluctuations of 
donor cell chimerism were sequentially examined in peripheral blood of individual 
recipients, each symbol represents an individual recipient mouse (n=7). (B) 
Secondary transplantations were performed to further evaluate stem cell 
repopulating ability. Two or three primary recipients from each genotype were 
selected and 3 X 106 bone marrow LDMC were transplanted into each lethally 
irradiated recipient (2-3 recipients per primary mouse). Each symbol represents 
an individual recipient mouse. For the Fancc-/-;Fancg-/- genotype, the mouse 
numbers correspond with those shown in Figure 16A. There were 3 secondary 
recipients transplanted with cells from mouse #2, 3 from mouse #5 and 2 from 
mouse #7. This shows the continuous increase in variability of the chimerism for 
the Fancc-/-;Fancg-/- donor cells. 
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To further evaluate this unstable chimerism and the stem cell functionality, 
secondary transplantations were performed for all genotypes and only those 
recipients transplanted with the Fancc-/-;Fancg-/- donor cells had a continued 
increase in chimerism variability (Figure 16B) (Secondary transplantations 
performed by Dr. Samantha Ciccone, chimerism analysis performed by both Dr. 
Samantha Ciccone and Anna C. Leath, histological analysis performed by Anna 
C. Leath). The dramatic increase in test cell chimerism in some of the recipients 
suggests the development of clonal evolution of repopulating cells. 
To evaluate whether the progressive increase in test cell chimerism in 
Fancc-/-;Fancg-/- BMC recipients was associated with the development of 
hematologic malignancies, spleen and bone marrow were harvested from the 
recipient mice. Recipients reconstituted with either WT, Fancc-/- or Fancg-/- cells 
all had normal splenic architecture and histology (data not shown). In contrast, 
recipient mice reconstituted with Fancc-/-;Fancg-/- BMC showed a range of 
hematologic abnormalities including myeloid malignancies and aplastic anemia 
(Figure 15C, Table IV). The spleens from these recipients were enlarged and 
displayed complete disruption of normal splenic architecture and abnormal cell 
histology (Figure 15C). 
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Table IV. Mice reconstituted with Fancc-/-;Fancg-/- donor cells have an 
increased risk of myeloid malignancy. This summary represents all of the data 
from two cohorts of competitive repopulation transplantations and one cohort of 
non-competitive transplantations. 
Donor Cell Genotype 
 
 Malignancy 
 WT  0/16 
 Fancc-/- 
 
 0/15 
 Fancg-/- 
 
 0/16 
 Fancc-/-;Fancg-/- 
 
 9/17 
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To confirm that these phenotypes were indeed due to reconstitution of the 
hematopoietic system by the donor cells and not the recipient’s endogenous 
BMC, CD45.2+ cells were sorted, cultured for growth of progenitors in semisolid 
medium and individual colonies were genotyped. Less than 10% of the colonies 
were from the recipient’s residual BMC consistent with previous results (data not 
shown) (Si, Pulliam et al. 2008). 
Cytogenetic evaluation showed that only the transplanted Fancc-/-;Fancg-
/- BMC accumulated genetic abnormalities such as aneuploidy and multiple 
chromosomal translocations (Figure 17, Tables V and VI) (G-banding and SKY 
performed by Dr. Gail Vance’s lab). Collectively, the spectra of hematologic 
abnormalities observed are consistent with phenotypes found in FA patients such 
as hypoplastic bone marrow and hematopoietic malignancies (Butturini, Gale et 
al. 1994). 
In an assay comparable to that used to identify a patient’s 
complementation group, only complementation of both Fancc and Fancg in 
Fancc-/-;Fancg-/- myeloid progenitors resulted in resistance to MMC. Cells that 
contain a transgene that complements only one gene were still hypersensitive to 
MMC (Figure 18). 
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Figure 17 
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Figure 17. Spectral karyotyping shows aneuploidy and chromosomal 
translocations in Fancc-/-;Fancg-/- cells from the bone marrow of non-
competitive recipients. WT shows a normal spectral karyogram. See Tables V 
and VI for detailed descriptions of the chromosomal abnormalities found. 
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Table V. G-banding analysis confirms chromosomal abnormalities in 
Fancc-/-;Fancg-/- cells. 
Genotype  Cytogenetic Results # of cells 
analyzed* 
WT  40,XY [5] 5 
Fancc-/-;Fancg-/-  41~43,XX,+mar1,+mar2,+mar3 [cp 6]/ 
40,XX [5] 
12 
Fancc-/-;Fancg-/-  40,XY,der(1)t(1;10),dic(3;5),-5, 
der(6)t(6;18), der(9)t(6;9),-10, 
+mar1,+mar2 [cp 5]/ 40,XY [6] 
15 
Fancc-/-;Fancg-/-  40,XX,-1,?del(2),+der(2)t(2;6),t(3;13), 
+del(4),-6, del(11),+der(11)t(1;11),del(14), 
?15,-16 [5]/ 40, XX[6] 
11 
Fancc-/-  40,XX[9]/Nonclonal[1] 10 
*Cells not included in the nomenclature include nonclonal cells and normal cells 
of the opposite sex. 
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Table VI. Spectral karyotyping (SKY) analysis confirms chromosomal 
abnormalities in Fancc-/-;Fancg-/- cells. 
Genotype   SKY Results # of cells 
analyzed* 
WT  40,XY [4] 5 
Fancc-/-;Fancg-/-  41~45,XX,+mar1,+mar2,+mar3 [cp 2]/  
40,XX [7] 
12 
Fancc-/-;Fancg-/-   40,XY,der(1)t(1;10),dic(3;5),-5,der(6)t(6;18), 
der(9)t(6;9),-10,+mar1,+mar2 [2]/ 40,XY [7] 
12 
Fancc-/-;Fancg-/-   40, XX,-1,?del(2), +der(2)t(2;6), t(3;13), 
+del(4),-6,del(11),+der(11)t(1;11),del(14), 
?15,-16 [1]/ 40,XX [2] 
3 
*Cells not included in the nomenclature include nonclonal cells and normal cells 
of the opposite sex. 
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 Figure 18 
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Figure 18. Correction of both the Fancc and Fancg defect results in a 
correction of MMC hypersensitivity. Bone marrow LDMC from WT or Fancc-/-
;Fancg-/- mice were transduced overnight, as published previously (Si, Pulliam et 
al. 2008), with either a foamy virus EGFP reporter construct, a single foamy virus 
with FANCC/EGFP or FANCG/EGFP or with both viruses to correct both genes. 
Shown here are WT and Fancc-/-;Fancg-/- cells with reporter only, the Fancc-/-
;Fancg-/- cells with correction of both genes and Fancc-/-;Fancg-/- cells with 
correction of only one gene. Colony assays in the presence of MMC were 
performed as described previously (Si, Pulliam et al. 2008). The percentage 
shown was determined by the (# of CFU in MMC)/(# of CFU without MMC)*100. 
Mean ± SEM is shown, n=6 for Fancc-/-;Fancg-/-, n=3 for WT. *p<0.05 as 
compared to WT or Fancc-/-;Fancg-/- corrected with both genes by ANOVA. 
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To rule out the possibility that the observed hematopoietic phenotypes 
occur following loss of any two core complex proteins, our lab intercrossed the 
Fanca-/- and Fancc-/- mice (Dr. Yue Si). The Fanca-/-;Fancc-/- mice did not 
develop bone marrow aplasia or myeloid malignancies although they failed to 
monoubiquitinate FANCD2 (Y.S. and D.W.C., unpublished data, 28 June 2005). 
These data are consistent with a previous study utilizing an intercross of Fancc-/- 
mice with Fanca hypomorphic mice where Fancc-/- and Fanca-/- mice had 
similar numbers of myeloid progenitors and comparable MMC hypersensitivity to 
each other and Fanca-/-;Fancc-/- mice (Noll, Battaile et al. 2002).
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Numerous elegant studies have demonstrated the seminal role of ID 
complex monoubiquitination and phosphorylation in the activation of downstream 
effectors of DNA repair (Bagby and Alter 2006; Taniguchi and D'Andrea 2006; 
Ishiai, Kitao et al. 2008; Wang 2008; de Winter and Joenje 2009). Additionally, 
the FA core complex proteins are collectively required for activation of the ID 
complex and the loss of any single FA core complex protein is sufficient to 
prevent ID complex monoubiquitination (Taniguchi and D'Andrea 2006; de Winter 
and Joenje 2009). However, recent studies have provided cellular and 
biochemical evidence that the FA core complex proteins have functions that are 
independent of their respective roles in activating FANCD2 (Pang, Christianson 
et al. 2001; Pang, Christianson et al. 2002; Zhang, Li et al. 2004; Gordon, Alon et 
al. 2005; Hussain, Wilson et al. 2006; Leveille, Ferrer et al. 2006; 
Mukhopadhyay, Leung et al. 2006; Wilson, Yamamoto et al. 2008).  
Discussion 
Specifically, FANCC and FANCG, the human homologues of the genes 
intercrossed here, have been shown to participate in molecular networks outside  
of the FA core complex. For example, FANCG has recently been shown to have 
a critical role in supporting the function of mitochondrial periredoxin-3 that is 
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implicated in rendering FA cells a characteristic hypersensitivity to oxidative 
stress (Mukhopadhyay, Leung et al. 2006). Also, FANCG but not FANCC has 
been shown to form a complex with FANCD1, FANCD2 and XRCC3, and this 
complex is thought to function in homologous recombination repair (Wilson, 
Yamamoto et al. 2008). Similarly, FANCC is known to participate in the PKR 
signaling pathway, while the other FA core complex proteins are not (Pang, 
Christianson et al. 2002; Zhang, Li et al. 2004). 
Whether mechanistically these interactions contribute to BMF and myeloid 
malignancies independent of the ID complex is unclear. However, given the 
distinct hematopoietic phenotypes observed in syngeneic Fancc and Fancg 
deficient mice and observations that Fancc-/- and Fancg-/- mice do not develop 
overt BMF, the hypothesis that Fancc and Fancg may cooperate in stem cell 
control by conducting a genetic intercross was tested. The prediction was that if 
these two FA core complex proteins are multifunctional and influence 
hematopoietic cell survival independent of their role in the FA nuclear core 
complex, then the Fancc/Fancg double knockout mice would display distinct 
pathological phenotypes from those found in mice with inactivation of Fancc or 
Fancg only. Evidence that the phenotypes observed in Fancc-/-;Fancg-/- BMC 
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were specific to disruption of both the Fancc and Fancg genes was confirmed by 
the observation that Fancc-/-;Fancg-/- myeloid progenitors expressing 
transgenes that complement both Fancc and Fancg were resistant to MMC while 
Fancc-/-;Fancg-/- cells that contain a transgene that complements Fancc or 
Fancg only were hypersensitive to MMC. While this result was hypothesized, the 
apparent correction to levels comparable to WT raises further questions. Since 
the transduction efficiency is not 100%, but there was still a correction to near 
WT levels, it is then reasonable to hypothesize that the correction is even better 
than 100%. Future experiments may address this by sorting for transduced cells 
before plating progenitor assays. 
Interestingly, the Fancc-/-;Fancg-/- mice developed BMF, myelodysplasia 
and complex cytogenetic abnormalities that are characteristic of bone marrow 
phenotypes observed in individuals with Fanconi anemia yet not observed in the 
single knockout mice. Prior in vitro data supporting cooperation of FANCC and 
FANCG in the human system include a report in an adenocarcinoma cell line that 
genetic disruption of FANCC and FANCG increased cytogenetic abnormalities 
(Gallmeier, Calhoun et al. 2006). The model described here provides an in vivo 
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platform that may be useful for questions regarding the pathogenesis of MDS 
and BMF. 
Cross breeding of Fanconi mutant mice with other mice with inactivating 
gene mutations of non-FA genes has been reported and resulted in increased 
tumor formation and bone marrow hypocellularity (Hadjur, Ung et al. 2001; Freie, 
Li et al. 2003; Houghtaling, Granville et al. 2005) though the majority of 
malignancies observed in those crosses were not representative of those 
commonly observed in FA patients. The development of the model outlined here 
provides interesting opportunities for modeling of therapeutic protocols. The 
failure of established single knockout mice to develop BMF has been a major 
limitation in translational preclinical applications to test questions surrounding 
stem cell engraftment, homing and gene transfer. One such hypothesis is that FA 
patients with hypoplasia or overt BMF will not require myelopreparation prior to 
transplantation of autologous genetically corrected stem/progenitor cells but the 
lack of a spontaneous BMF model has limited effectively testing this question 
prior to phase 1 trials. The Fancc-/-;Fancg-/- mice now provide a model that can 
more accurately allow testing of this experimental question. 
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Given the phenotypes observed in the Fancc-/-;Fancg-/- mice, it was 
pertinent to ask whether these phenotypes would be broadly applicable to any 
intercross of FA core complex proteins. Current experimental data suggests that 
this is not the case. While consistent pathological phenotypes were observed in 
the Fancc-/-;Fancg-/- mice, using a similar experimental design as outlined in 
studies shown in this manuscript, intercrossed mice that are deficient in both 
Fanca and Fancc have no observable cooperative defects in stem cell function. 
These data are consistent with previous studies (Noll, Battaile et al. 2002) that 
did not report biological changes in hematopoietic progenitor cells exposed to 
alkylating agents in vitro. This suggests that there is something unique in the 
function of Fancg, since Fancc is common to both intercrosses and studies to 
assess this function of Fancg are an important area of future investigation. 
In summary, these data provide the first genetic and in vivo evidence that 
the combined inactivation of Fancc and Fancg lead to a cooperative impairment 
in hematopoietic stem cell function, supporting the hypothesis that FANCC and 
FANCG function in divergent molecular pathways of relevance to hematopoiesis 
in addition to their roles in ID complex monoubiquitination. Our observations also 
reveal that the Fancc-/-;Fancg-/- mouse is a model that best recapitulates the 
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spontaneous clinical hematopoietic phenotypes of human FA, including 
malignancies and bone marrow aplasia. Therefore, the Fancc-/-;Fancg-/- double 
knockout mouse may be useful in studies of pathogenesis and experimental 
treatment of FA-related hematopoietic diseases. 
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CHAPTER 6 
Future directions 
 
This project has focused on the evaluation of a novel gene transfer vector 
and protocol for FA as well as on developing a genetic model that mimics the 
disease phenotype observed in patients. This genetic model will hopefully lead to 
a more complete understanding of the FA gene products’ effects on 
hematopoiesis. 
Our data show that the single knockout Fanca-/- and Fancc-/- mice display 
the same G-CSF hematopoietic mobilization defect as FA patients. Therefore, 
these mouse models are useful for testing new mobilizing agents such as 
AMD3100. Our data show that AMD3100 is effective at augmenting G-CSF 
mobilization in these mice and future studies may address this in FA patients.  
The mechanism of AMD3100 and/or G-CSF mobilization is not fully 
understood. Additionally, the FA pathway is not fully understood. The Fanca-/- 
and Fancc-/- mouse models provide a unique platform for investigation of the 
mobilization pathways in the FA setting, where one mobilization pathway is 
inherently deficient (G-CSF) and the other is intact (AMD3100). Additionally, it 
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will be interesting to see if other FA mouse models (and patient’s with the 
homologous complementation group) have the same phenotype in response to 
the different mobilizing agents or the combination. If they do not then that would 
point to a common function of the proteins (FANCA, FANCC and any others with 
a similar phenotype) related to mobilization outside of the traditional FA pathway. 
Recently there have been many papers published on the interactions of FA 
proteins outside of the pathway, but none directly related to mobilization.  
From the multi-lineage analysis of the transplanted mobilized cells a 
lymphoid bias is observed for the Fancc-/- mobilized cells, which is not present in 
the other genotypes. Normally as mice age there is a shift toward the myeloid 
lineage (Waterstrat and Van Zant 2009). One hypothesis to explain this involves 
Notch signaling. It has been shown that Notch activity is required for lymphoid 
differentiation but not myeloid; however, in a mouse model that fails to 
glycosylate Notch the mice develop MPD, so Notch does play some role in the 
regulation of myeloid maintenance (Bigas, Robert-Moreno et al. 2010). FA 
patients typically get AML and not acute lymphoblastic leukemia (Kutler, Singh et 
al. 2003), which may be explained by an error in Notch regulation. Further 
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evaluation of Notch signaling in both this and the double knockout model may 
provide a new explanation for the development of BMF in FA. 
While the benefits of transplantation using mobilized donor cells as 
compared to BMC are well established (Rosenbeck, Srivastava et al. 2010), 
determining whether or not mobilized cells respond to transduction in a manner 
similar to aspirated BMC is of utmost importance before these protocols move to 
clinical trials. Recent evidence has shown that G-CSF mobilized CD34+ cells 
collected from the PB of healthy patients is efficiently transduced by a lentiviral 
vector with a short transduction protocol (Millington, Arndt et al. 2009). While our 
previous studies show our FV vector is capable of efficiently transducing BMC 
with a single overnight transduction (Si, Pulliam et al. 2008) and the studies here 
show that the FV vector is able to transduce and correct mobilized murine long-
term repopulating cells, further studies are needed before progressing to clinical 
trials.  
Initial experiments should focus on competitive repopulation experiments 
with secondary transplantations to demonstrate the self-renewal capacity of the 
transduced mobilized cells. Experiments will then be performed with cord blood 
CD34+ cells from normal patients that will provide a baseline level of transduction 
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and repopulating ability in NOD/SCID2 mice. Further experiments will expand to 
include mobilized CD34+ cells from normal patients. Ideally the transduction 
would then be tested on CD34+ cells from FA patients and the correction of MMC 
hypersensitivity would be determined in progenitor assays. 
Experiments here have utilized a novel FV vector. The construct used 
contains the SFFV promoter, which has been associated with clonal outgrowth in 
clinical trials for chronic granulomatous disease (Stein, Ott et al. 2010). Future 
experiments will include evaluation of other promoters that will ideally still be 
effective but will not result in adverse events such as transactivation leading to 
malignancy. Additionally, investigation of ways to enhance transgene expression 
such as codon optimization and the addition of insulator elements will be 
pursued. 
The development of a murine model that recapitulates the patient disease 
phenotype opens multiple new avenues of investigation not available before. This 
model provides genetic evidence that the core complex gene products (FANCC 
and FANCG) have functions independent of the core complex and separate from 
each other. Within the FA scientific community there has been debate for many 
years on whether core complex proteins have functions independent of the core 
 121 
complex. Now that there is a genetic model illustrating these independent roles of 
core complex proteins, future lines of investigation may focus on not only the FA 
pathway, but also the other functions of the FA proteins. Knowing these functions 
may help in recognition or discovery of novel therapeutic treatments for FA.  
Since the first FA mouse model was developed there has been an 
interesting question left unanswered: why do the single knockout mice not 
recapitulate the patient disease phenotype? One hypothesis involves the 
environment in which the mice live. While children with FA are living in the world 
where they are exposed to viruses, bacteria and radiation daily, the mice are kept 
in a sterile facility. It is known that the FA cells are hypersensitive to inhibitory 
cytokines, which are released by the immune system especially during infections. 
So a child with FA who acquires an infection may experience an associated loss 
of HSC. The mice in our facility would not experience this naturally. Additionally, 
children are exposed to various DNA damaging agents in their environment that 
the mice are not. The difference in environment may be compounded by the 
difference in lifespan for the mice versus human patients. Future experiments 
could involve challenging the mice with various infectious agents. 
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The follow up question to why do the single knockout mice not display the 
patient disease phenotype is why do the double knockout mice display the 
phenotype? One hypothesis is that the result of the abrogation of the separate 
functions of FANCC and FANCG independent of the core complex is a mutator 
phenotype in the Fancc-/-;Fancg-/- cells which is not present in the single 
knockout cells. Our data from the cytogenetic analysis would support this 
hypothesis as only the double knockout cells had cytogenetic abnormalities. Why 
then do patients only need one gene to be mutated to display the same disease 
phenotype? In addition to the environmental factors and lifespan difference 
mentioned in the previous paragraph, another hypothesis is that in FA patients 
the HSC have experienced a second hit where a second gene has been knocked 
out or is no longer being expressed. Typically patients are identified when they 
come to the clinic with some sort of BMF. The patient’s skin or peripheral blood 
cells are tested for hypersensitivity to DNA cross-linking agents and further 
complementation analysis is done to determine the specific complementation 
group. If any of the HSC have had a second hit it may not be detected by this 
procedure. Therefore, it is possible that there may indeed be an acquired double 
knockout in the bone marrow of an FA patient. Another possibility is that although 
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a gene may be intact, it may be down regulated through various mechanisms. 
Work with our collaborator has allowed us to compare expression profiles from 
our DKO model with those from patients before and after the onset of BMF. This 
data has led to selection of specific targets that will be investigated. 
When considering gene transfer therapy or bone marrow transplantation 
for FA, whether or not any myelopreparative regimen is necessary has been a 
long-standing question. It has been shown that the agents typically used for 
myelopreparation can cause adverse events in FA patients (MacMillan and 
Wagner 2010) and also that the non-corrected FA murine cells are 
hypersensitive to DNA cross-linking agents and may transform into malignant 
clones (Li, Le Beau et al. 2005). However, if no conditioning regimen is used, 
there may be little to no long-term engraftment as seen in previous clinical trials 
(Liu, Kim et al. 1999; Kelly, Radtke et al. 2007) and FA single knockout models 
not experiencing BMF (Si, Ciccone et al. 2006). It has been shown that WT cells 
and the corrected FA cells do have a competitive advantage over the non-
corrected FA cells in repopulation of a lethally irradiated mouse (Haneline, Li et 
al. 2003; Si, Pulliam et al. 2008). Therefore, the WT cells or corrected FA cells 
may have an advantage over the endogenous hematopoietic cells in an FA 
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murine model exhibiting BMF. It has been difficult to thoroughly address this 
question in the clinic and previously there was not a murine model of FA that 
displayed spontaneous BMF. The novel murine model described here provides 
an important platform for evaluation of myelopreparative conditioning regimens. 
Initial experiments will involve transplantation of WT cells transduced with 
a GFP reporter construct or corrected Fancc-/- cells into mice displaying BMF, at 
a dose equivalent to that acceptable for patients. These transplantation 
experiments will determine whether the mice displaying BMF can be rescued 
with transplantation in the absence of myelopreparation. 
Our lab has shown previously that administration of IFN-γ allows for 
engraftment of WT cells in Fanca-/-, Fancc-/- and Fancg-/- mice (Li, Yang et al. 
2004; Si, Ciccone et al. 2006). Therefore, IFN-γ may be useful as a 
myelopreparative agent during HSC transplantation for FA patients. Future 
experiments will address the possibility of using IFN-γ to precondition the bone 
marrow of FA double knockout mice. Fancc-/-;Fancg-/- mice will be treated with 
IFN-γ and then transplanted with corrected Fancc-/- cells, or cells transduced 
with the reporter construct only, either Fancc-/- or WT. If successful, limiting 
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dilutions may be done to determine the minimum number of corrected cells 
necessary for engraftment and reconstitution of the hematopoietic system. 
In the Fancc-/-;Fancg-/- model, a portion of the mice also present with 
malignancies. This malignant transformation allows us to address another 
interesting question. It is possible that a malignant clone may either directly or 
indirectly inhibit the engraftment of transplanted HSC, which would have 
significant implications for bone marrow transplantation procedures. The novel 
model presented here will allow for evaluation of whether or not such an event is 
occurring and an investigation of the mechanism, which could lead to 
identification of potential therapeutics. 
Another important aspect of this model is the opportunity to compare 
expression profiles before and after the progression to BMF and also to MDS. 
Microarray data was collected for these different groups and analysis of the data 
has led to specific gene targets that are elevated in BMF samples as compared 
to normal samples and then decreased in MDS samples. This was compared to 
data from FA patients before and after the onset of BMF and/or MDS provided by 
our collaborator, Dr. Grover Bagby. Some of the genes identified are known to be 
involved in spindle checkpoint control, which could provide an explanation for the 
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aneuploidy observed in the mouse model. Further exploration of these gene 
targets as instigators of cancer will be performed. 
This project has evaluated an alternative mobilization protocol for FA 
HSC/HPC; currently there is a clinical trial of this protocol recruiting FA patients. 
Data presented here also demonstrate successful transduction of these 
mobilized cells with a novel FV gene transfer vector. And lastly, this project 
resulted in the development of a novel murine model that recapitulates the 
hematopoietic disease phenotype observed in patients, which will allow for 
assessment of future treatments, including gene transfer therapy. 
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